fenofibrate has been researched along with Diabetes Mellitus, Adult-Onset in 337 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 9.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 9.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| " We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation." | 9.27 | Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. ( Ansquer, JC; Best, JD; Buizen, L; d'Emden, MC; Davis, TME; Feher, MD; Flack, J; Foucher, C; Gebski, V; Hedley, J; Jenkins, AJ; Keech, AC; Kesaniemi, YA; Li, L; McGill, N; Scott, RS; Sullivan, DR; Waldman, B, 2018) |
| "Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies." | 9.19 | Effects of fenofibric acid on diabetic macular edema: the MacuFen study. ( Ansquer, JC; Aubonnet, P; MacuFEN Study Investigators, FT; Massin, P; Peto, T, 2014) |
| " The aim of our study was to explore the changes in circulating Pref-1 concentrations in female subjects with obesity (OB) (n=19), females with obesity and type 2 diabetes mellitus (T2DM) (n=22), and sex- and age-matched healthy control subjects (C) (n=22), and to study its modulation by very low calorie diet (VLCD), acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp, and 3 months' treatment with PPAR-α agonist fenofibrate." | 9.17 | Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment. ( Drapalova, J; Haluzik, M; Haluzikova, D; Kavalkova, P; Lacinova, Z; Matoulek, M; Mraz, M; Novak, D; Roubicek, T; Touskova, V; Trachta, P; Urbanova, M, 2013) |
| "We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 9.14 | Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( D'Emden, M; Ehnholm, C; Fulcher, G; Keech, A; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Tse, D, 2009) |
| "To compare lipid lowering profile and effects on markers of inflammation of rosuvastatin and fenofibrate in patients with type 2 diabetes with low high density lipoprotein (HDL) cholesterol (CH)." | 9.14 | [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation]. ( Gratsianskiĭ, NA; Iavelov, IS; Masenko, VP; Polenova, NV; Vaulin, NA, 2009) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 9.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| "To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 9.14 | Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Burgess, DC; Davis, TM; Hunt, D; Keech, AC; Kesäniemi, YA; Laakso, M; Lehto, S; Li, L; Mann, S; Sy, RW; Williamson, E; Zannino, D; Zhang, J, 2010) |
| " The aim of our study was to assess serum FABP levels in obese patients with type 2 diabetes mellitus (T2DM) before and after 3 months of treatment with PPAR-alpha agonist fenofibrate (F) and to explore the relationship of FABP to biochemical parameters and measures of insulin sensitivity assessed by hyperinsulinemic-isoglycemic clamp." | 9.14 | Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. ( Adamíková, A; Anderlová, K; Doležalová, R; Haluzík, M; Haluzík, MM; Haluzíková, D; Housová, J; Svacina, S, 2009) |
| " Therefore, the objective of this 2-group parallel study was to examine the differential effects of a 6-week treatment with atorvastatin or fenofibrate on in vivo kinetics of apo B-48 and B-100 in men with type 2 diabetes mellitus with marked hypertriglyceridemia." | 9.13 | Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. ( Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| " The objective of this 2-group parallel study was to investigate the differential effects of a 6-week treatment with either atorvastatin 20 mg/d alone (n = 19) or micronized fenofibrate 200 mg/d alone (n = 19) on inflammation, cell adhesion, and oxidation markers in type 2 diabetes mellitus subjects with marked hypertriglyceridemia." | 9.13 | Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "The aim of this study was to evaluate whether and to what extent fenofibrate (F), metformin (M) or a combination of these drugs improve characteristics of the metabolic syndrome (MetS)." | 9.12 | Normalization of metabolic syndrome using fenofibrate, metformin or their combination. ( Kastelein, JJ; Nieuwdorp, M; Stroes, ES, 2007) |
| "Treatment with fenofibrate in individuals with type 2 diabetes mellitus reduces the need for laser treatment for diabetic retinopathy, although the mechanism of this effect does not seem to be related to plasma concentrations of lipids." | 9.12 | Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. ( Colman, PG; Crimet, DC; d'Emden, MC; Davis, TM; Keech, AC; Laatikainen, LT; Merrifield, A; Mitchell, P; Moffitt, MS; O'Connell, RL; O'Day, J; Simes, RJ; Summanen, PA; Taskinen, MR; Tse, D; Williamson, E, 2007) |
| "The Diabetes Atherosclerosis Intervention Study (DAIS) examined the effects of fenofibrate or placebo on the progression of coronary artery disease (CAD) in 418 type 2 diabetic subjects with dyslipidemia." | 9.11 | Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. ( Frohlich, J; Genest, J; Steiner, G, 2004) |
| " Plasma insulin, antiinsulin antibodies, lipid parameters and the insulin sensitivity index (ISI) were measured at entry and after a 3-month therapy with 200 mg micronized fenofibrate daily." | 9.11 | Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. ( Belowski, D; Kalina, M; Kalina, Z; Kochanski, L; Okopien, B; Wysocki, J, 2004) |
| "The aim of this study was to compare the efficacy and safety profile of fluvastatin + fenofibrate combination therapy and those of fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus (DM), and coronary heart disease (CHD) (ie, high risk for cardiovascular disease [CVD])." | 9.11 | Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. ( Bertone, G; Ciccarelli, L; Cicero, AE; Derosa, G; Piccinni, MN; Roggeri, DE, 2004) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 9.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "To review clinical and experimental data for fenofibrate as a possible systemic treatment for diabetic retinopathy." | 8.88 | Fenofibrate - a potential systemic treatment for diabetic retinopathy? ( Mitchell, P; Simó, R; Wong, TY, 2012) |
| "This study aimed to determine the association between fenofibrate added to statin therapy and diabetic retinopathy progression." | 8.31 | Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study. ( Choi, J; Kim, NH; Kim, SG; Kim, YH; Lee, H, 2023) |
| "To assess the association between fenofibrate use and the progression from NPDR to VTDR, proliferative DR (PDR), or diabetic macular edema (DME)." | 8.12 | Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. ( Bavinger, JC; Meer, E; VanderBeek, BL; Yu, Y, 2022) |
| "These case reports aim to show that hyperfibrinogenemia is a risk factor for the progression and prognosis of peripheral arterial disease (PAD), in patients with and without diabetes mellitus type 2." | 7.88 | Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature). ( Antova, E; Bosevska, G; Bosevski, M; Krstevski, G; Mitevska, I, 2018) |
| "The role of cytokines in diabetic retinopathy (DR) and effects of fenofibrate on cytokines were explored by observing changes in serum IL-1β, TNF-α, VEGF, and Lp-PLA2 in different stages of DR and the intervention effect of oral fenofibrate on cytokines." | 7.85 | Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. ( Cui, T; Ju, HB; Li, LF; Song, J; Wang, S; Zhang, FX; Zhang, HY, 2017) |
| " We investigated the effect of fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, on RANTES in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia." | 7.83 | PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. ( Feng, X; Gao, X; Jia, Y; Wang, G; Xu, Y; Zhang, H, 2016) |
| "We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 7.77 | Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Ansquer, JC; Colman, P; Davis, TM; Dixon, P; Drury, PL; Ehnholm, C; Fassett, R; Flack, J; Keech, A; Pardy, C; Ting, R; Whiting, M; Zannino, D, 2011) |
| "Fenofibric acid + statin combination therapy in patients with mixed dyslipidemia and type 2 diabetes was well tolerated and resulted in more comprehensive improvement in the lipid/apolipoprotein profile than either monotherapy." | 7.76 | Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. ( Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K, 2010) |
| "Fenofibrate was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese patients." | 6.80 | Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. ( Abd El-Razek, RS; El-Hefnawy, MH; El-Mesallamy, HO; Noureldein, MH, 2015) |
| "Fenofibrate treatment decreased serum triglyceride concentrations, while both blood glucose and glycated hemoglobin increased after three months of fenofibrate administration." | 6.73 | Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. ( Anderlová, K; Bosanská, L; Dolezalová, R; Haluzík, M; Haluzíková, D; Housová, J; Kremen, J; Skrha, J, 2007) |
| "Patients with type 2 diabetes mellitus and no histories of coronary heart disease were evaluated (n = 498)." | 6.73 | Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). ( Anderson, JL; Horne, BD; Jensen, JR; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Yannicelli, HD, 2008) |
| "Diabetic retinopathy is a significant cause of vision impairment, especially affecting those of working age." | 6.52 | The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. ( Newman, D; Ong, J; Ooi, JL; Sharma, N, 2015) |
| "Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α." | 6.47 | Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. ( Keating, GM, 2011) |
| "Dyslipidemia is an important modifiable risk factor." | 6.46 | The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. ( Campbell, J; Mohiuddin, SM, 2010) |
| "Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor-alpha." | 6.44 | Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. ( Steiner, G, 2008) |
| "Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures." | 6.44 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. ( Croom, KF; Keating, GM, 2007) |
| "Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis." | 5.72 | Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. ( Falcão-Pires, I; Ferrão, D; Ferreira, JP; Leite-Moreira, A; Neves, JS; Rossignol, P; Saraiva, F; Sharma, A; Vasques-Nóvoa, F; Zannad, F, 2022) |
| "Two large-scale randomized clinical trials compared fenofibrate and placebo in diabetic patients with pre-existing retinopathy (FIELD study) or risk factors (ACCORD trial) on an intention-to-treat basis and reported a significant reduction in the progression of diabetic retinopathy in the fenofibrate arms." | 5.69 | G-estimation of structural nested mean models for interval-censored data using pseudo-observations. ( Brookhart, MA; Fine, J; Tanaka, S, 2023) |
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 5.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| "Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia." | 5.38 | Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, MF; Erkoc, R; Soyoral, YU, 2012) |
| " After establishing a dose-response curve for each drug, the drugs were orally administered for 3 weeks either alone or in combination." | 5.37 | Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice. ( Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY, 2011) |
| "Fenofibrate treatment resulted in normalization of abnormal lipid profiles and a reduction in Fb level." | 5.35 | Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes. ( Bukowska, H; Chełstowski, K; Jastrzebska, M; Klimek, K; Mierzecki, A, 2009) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 5.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 5.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| " We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation." | 5.27 | Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. ( Ansquer, JC; Best, JD; Buizen, L; d'Emden, MC; Davis, TME; Feher, MD; Flack, J; Foucher, C; Gebski, V; Hedley, J; Jenkins, AJ; Keech, AC; Kesaniemi, YA; Li, L; McGill, N; Scott, RS; Sullivan, DR; Waldman, B, 2018) |
| "In people with type 2 diabetes at high risk for cardiovascular disease, intensive glycemic control may result in a long-term reduction in macroalbuminuria; however, intensive BP control and fenofibrates may increase the risk for adverse kidney events." | 5.27 | Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. ( Buse, JB; Craven, TE; Ismail-Beigi, F; Katz, L; Mottl, AK; Mychaleckyj, JC; Papademetriou, V; Pedley, CF; Sigal, RJ; Simmons, DL, 2018) |
| "This study investigated whether the beneficial effects of intensive glycemic control and fenofibrate treatment of dyslipidemia in reducing retinopathy progression demonstrated in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study persisted beyond the clinical trial." | 5.22 | Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. ( , 2016) |
| "Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies." | 5.19 | Effects of fenofibric acid on diabetic macular edema: the MacuFen study. ( Ansquer, JC; Aubonnet, P; MacuFEN Study Investigators, FT; Massin, P; Peto, T, 2014) |
| " The aim of our study was to explore the changes in circulating Pref-1 concentrations in female subjects with obesity (OB) (n=19), females with obesity and type 2 diabetes mellitus (T2DM) (n=22), and sex- and age-matched healthy control subjects (C) (n=22), and to study its modulation by very low calorie diet (VLCD), acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp, and 3 months' treatment with PPAR-α agonist fenofibrate." | 5.17 | Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment. ( Drapalova, J; Haluzik, M; Haluzikova, D; Kavalkova, P; Lacinova, Z; Matoulek, M; Mraz, M; Novak, D; Roubicek, T; Touskova, V; Trachta, P; Urbanova, M, 2013) |
| "We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 5.14 | Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( D'Emden, M; Ehnholm, C; Fulcher, G; Keech, A; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Tse, D, 2009) |
| "Fenofibrate is a peroxisome proliferator-activated receptor-alpha (PPARalpha) activator that has been clinically used to treat dyslipidemia and insulin resistance." | 5.14 | Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. ( Bao, Y; Huang, P; Jia, W; Liu, Y; Lu, J; Wei, L; Wu, H; Xiang, K, 2009) |
| "To compare lipid lowering profile and effects on markers of inflammation of rosuvastatin and fenofibrate in patients with type 2 diabetes with low high density lipoprotein (HDL) cholesterol (CH)." | 5.14 | [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation]. ( Gratsianskiĭ, NA; Iavelov, IS; Masenko, VP; Polenova, NV; Vaulin, NA, 2009) |
| "OBJECTIVE To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors, and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia." | 5.14 | Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. ( Krysiak, R; Okopien, B; Pruski, M, 2009) |
| "To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 5.14 | Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Burgess, DC; Davis, TM; Hunt, D; Keech, AC; Kesäniemi, YA; Laakso, M; Lehto, S; Li, L; Mann, S; Sy, RW; Williamson, E; Zannino, D; Zhang, J, 2010) |
| "Although fenofibrate was associated with less progression of albuminuria in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, it is unknown if it has any effect on renal function." | 5.14 | Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. ( Forsblom, C; Groop, PH; Hiukka, A; Leinonen, ES; Sundvall, J; Taskinen, MR, 2010) |
| "The combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone." | 5.14 | Effects of combination lipid therapy in type 2 diabetes mellitus. ( Bigger, JT; Buse, JB; Byington, RP; Crouse, JR; Cushman, WC; Elam, MB; Friedewald, WT; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, RH; Ismail-Beigi, F; Leiter, LA; Linz, P; Lovato, LC; Probstfield, J; Simons-Morton, DG, 2010) |
| "9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg)." | 5.14 | Effects of medical therapies on retinopathy progression in type 2 diabetes. ( Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U, 2010) |
| "Randomized, open-label cross-over study investigating the effect of fenofibrate (160 mg), atorvastatin (10 mg), and combination of both in patients with type 2 diabetes mellitus and atherogenic dyslipidemia." | 5.14 | Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. ( Cariou, B; Costet, P; Guyomarc'h Delasalle, B; Hoffmann, MM; Konrad, T; Winkler, K, 2010) |
| " The aim of our study was to assess serum FABP levels in obese patients with type 2 diabetes mellitus (T2DM) before and after 3 months of treatment with PPAR-alpha agonist fenofibrate (F) and to explore the relationship of FABP to biochemical parameters and measures of insulin sensitivity assessed by hyperinsulinemic-isoglycemic clamp." | 5.14 | Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. ( Adamíková, A; Anderlová, K; Doležalová, R; Haluzík, M; Haluzík, MM; Haluzíková, D; Housová, J; Svacina, S, 2009) |
| "The aim of this substudy was to ascertain whether long-term treatment with fenofibrate reduces surrogate measures of atherosclerosis, biomarkers of inflammation, and endothelial activation in patients with type 2 diabetes." | 5.13 | Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. ( Hiukka, A; Hulten, LM; Keech, AC; Leinonen, ES; Salonen, JT; Taskinen, MR; Tuomainen, TP; Watanabe, H; Westerbacka, J; Wiklund, O; Yki-Järvinen, H, 2008) |
| " Therefore, the objective of this 2-group parallel study was to examine the differential effects of a 6-week treatment with atorvastatin or fenofibrate on in vivo kinetics of apo B-48 and B-100 in men with type 2 diabetes mellitus with marked hypertriglyceridemia." | 5.13 | Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. ( Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| " The objective of this 2-group parallel study was to investigate the differential effects of a 6-week treatment with either atorvastatin 20 mg/d alone (n = 19) or micronized fenofibrate 200 mg/d alone (n = 19) on inflammation, cell adhesion, and oxidation markers in type 2 diabetes mellitus subjects with marked hypertriglyceridemia." | 5.13 | Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "We assessed the additive effect of dual peroxisome proliferators activated receptors (PPAR) alpha/gamma induction, achieved by the addition of fenofibrate to rosiglitazone, on metabolic control and diabetic dyslipidemia." | 5.12 | The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. ( Altuntas, Y; Basat, O; Seber, S; Ucak, S, 2006) |
| "Patients (n = 300) with type II diabetes, mixed dyslipidemia (2 or more of low-density lipoprotein > or =100 mg/dl, triglycerides > or =200 mg/dl, or high-density lipoprotein <40 mg/dl), and no history of coronary heart disease were randomly assigned to receive simvastatin 20 mg, fenofibrate 160 mg, or a combination of simvastatin 20 mg and fenofibrate 160 mg daily." | 5.12 | The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. ( Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD, 2006) |
| "The aim of this study was to evaluate whether and to what extent fenofibrate (F), metformin (M) or a combination of these drugs improve characteristics of the metabolic syndrome (MetS)." | 5.12 | Normalization of metabolic syndrome using fenofibrate, metformin or their combination. ( Kastelein, JJ; Nieuwdorp, M; Stroes, ES, 2007) |
| "Treatment with fenofibrate in individuals with type 2 diabetes mellitus reduces the need for laser treatment for diabetic retinopathy, although the mechanism of this effect does not seem to be related to plasma concentrations of lipids." | 5.12 | Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. ( Colman, PG; Crimet, DC; d'Emden, MC; Davis, TM; Keech, AC; Laatikainen, LT; Merrifield, A; Mitchell, P; Moffitt, MS; O'Connell, RL; O'Day, J; Simes, RJ; Summanen, PA; Taskinen, MR; Tse, D; Williamson, E, 2007) |
| "The Diabetes Atherosclerosis Intervention Study (DAIS) examined the effects of fenofibrate or placebo on the progression of coronary artery disease (CAD) in 418 type 2 diabetic subjects with dyslipidemia." | 5.11 | Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. ( Frohlich, J; Genest, J; Steiner, G, 2004) |
| " Plasma insulin, antiinsulin antibodies, lipid parameters and the insulin sensitivity index (ISI) were measured at entry and after a 3-month therapy with 200 mg micronized fenofibrate daily." | 5.11 | Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. ( Belowski, D; Kalina, M; Kalina, Z; Kochanski, L; Okopien, B; Wysocki, J, 2004) |
| "The aim of this study was to compare the efficacy and safety profile of fluvastatin + fenofibrate combination therapy and those of fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus (DM), and coronary heart disease (CHD) (ie, high risk for cardiovascular disease [CVD])." | 5.11 | Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. ( Bertone, G; Ciccarelli, L; Cicero, AE; Derosa, G; Piccinni, MN; Roggeri, DE, 2004) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 5.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus." | 5.11 | Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. ( Barter, P; Best, J; Forder, P; Keech, A; Scott, R; Simes, J; Taskinen, MR, 2005) |
| "Diabetic subjects with mild hypercholesterolemia and good glycemic control may benefit from therapy with micronised fenofibrate because of the reduction in serum triglyceride, elevation in HDL cholesterol and a shift in LDL subfraction towards a non-atherogenic form." | 5.09 | Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. ( Chew, LS; Chio, LF; Lim, HS; Loh, LM; Shepherd, J; Tai, ES; Tan, CE, 2001) |
| " Fenofibrate significantly slowed the progression of early diabetic retinopathy by 30 to 40% within 4 to 5 years in patients with type 2 diabetes mellitus and pre-existing retinopathy at baseline." | 4.93 | Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review. ( Czupryniak, L; Gogtay, JA; Joshi, SR; Lopez, M, 2016) |
| " Fenofibrate may represent a useful therapeutic option for the treatment of atherogenic dyslipidemia in diabetic subjects." | 4.89 | Summarizing the FIELD study: lessons from a 'negative' trial. ( Elisaf, M; Mikhailidis, DP; Tsimihodimos, V, 2013) |
| "To review clinical and experimental data for fenofibrate as a possible systemic treatment for diabetic retinopathy." | 4.88 | Fenofibrate - a potential systemic treatment for diabetic retinopathy? ( Mitchell, P; Simó, R; Wong, TY, 2012) |
| " Evidence from the Fenofibrate Intervention and Event Lowering in Diabetes study suggests that fenofibrate reduces the risk of long-term macrovascular and microvascular type 2 diabetic complications, especially in patients demonstrating features of the metabolic syndrome." | 4.85 | Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. ( Toth, PP, 2009) |
| "This study aimed to determine the association between fenofibrate added to statin therapy and diabetic retinopathy progression." | 4.31 | Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study. ( Choi, J; Kim, NH; Kim, SG; Kim, YH; Lee, H, 2023) |
| "In 6002 Australian adults with type 2 diabetes and a median 5-year follow-up in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial, baseline socioeconomic status (SES) and self-reported education level were not related to development of on-trial sight-threatening diabetic retinopathy." | 4.31 | No relationship between socioeconomic status, education level and development and progression of diabetic retinopathy in type 2 diabetes: a FIELD trial substudy. ( Aryal, N; Brazionis, L; Colman, PG; Januszewski, AS; Jenkins, AJ; Keech, AC; Mitchell, P; O'Connell, R; O'Day, J; Rao, B; Shimmin, G, 2023) |
| "To assess the association between fenofibrate use and the progression from NPDR to VTDR, proliferative DR (PDR), or diabetic macular edema (DME)." | 4.12 | Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. ( Bavinger, JC; Meer, E; VanderBeek, BL; Yu, Y, 2022) |
| " In this study, we examine changes in use of two medications: fenofibrate, which was found to be ineffective when used with statins among patients with Type 2 diabetes (ACCORD lipid trial); and dronedarone, which was found to be unsafe in patients with permanent atrial fibrillation (PALLAS trial)." | 3.96 | Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm. ( Desai, NR; Dowd, B; Everhart, A; Herrin, J; Higuera, L; Jeffery, MM; Jena, AB; Karaca-Mandic, P; Ross, JS; Shah, ND; Smith, LB, 2020) |
| "In individual patients with T2DM, there is a wide range of absolute treatment effect of fenofibrate, and overall the fenofibrate treatment effect was larger in patients with dyslipidemia." | 3.88 | Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. ( Ginsberg, HN; Keech, AC; Koopal, C; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2018) |
| "Previous studies suggested that use of fenofibrate could significantly reduce the rate of progression into diabetic retinopathy (DR), and that retinal nerve fiber layer (RNFL) loss, which has been considered an important indicator for retinal neurodegeneration, might precede microvascular changes." | 3.88 | The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study. ( Qi, Y; Shi, R; Zhao, L, 2018) |
| "These case reports aim to show that hyperfibrinogenemia is a risk factor for the progression and prognosis of peripheral arterial disease (PAD), in patients with and without diabetes mellitus type 2." | 3.88 | Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature). ( Antova, E; Bosevska, G; Bosevski, M; Krstevski, G; Mitevska, I, 2018) |
| "The role of cytokines in diabetic retinopathy (DR) and effects of fenofibrate on cytokines were explored by observing changes in serum IL-1β, TNF-α, VEGF, and Lp-PLA2 in different stages of DR and the intervention effect of oral fenofibrate on cytokines." | 3.85 | Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. ( Cui, T; Ju, HB; Li, LF; Song, J; Wang, S; Zhang, FX; Zhang, HY, 2017) |
| " We investigated the effect of fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, on RANTES in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia." | 3.83 | PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. ( Feng, X; Gao, X; Jia, Y; Wang, G; Xu, Y; Zhang, H, 2016) |
| "Patients with type 2 diabetes mellitus die of cardiovascular disease (CVD) at rates 2-4 times higher than patients without diabetes but with similar demographic characteristics." | 3.82 | Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. ( Buse, JB; Byington, RP; Cushman, WC; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Margolis, KL; Probstfield, JL; Simons-Morton, DG, 2007) |
| "There is now consistent evidence from two major clinical trials (the Fenofibrate Intervention and Event Lowering in Diabetes and the Action to Control Cardiovascular Risk in Diabetes Eye) that fenofibrate arrests the progression of diabetic retinopathy in type 2 diabetic patients." | 3.81 | Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. ( Bogdanov, P; Carvalho, AR; Corraliza, L; Hernández, C; Simó, R, 2015) |
| "We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 3.77 | Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Ansquer, JC; Colman, P; Davis, TM; Dixon, P; Drury, PL; Ehnholm, C; Fassett, R; Flack, J; Keech, A; Pardy, C; Ting, R; Whiting, M; Zannino, D, 2011) |
| "Fenofibric acid + statin combination therapy in patients with mixed dyslipidemia and type 2 diabetes was well tolerated and resulted in more comprehensive improvement in the lipid/apolipoprotein profile than either monotherapy." | 3.76 | Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. ( Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K, 2010) |
| " Rosiglitazone reduced fasting glucose and insulin but induced weight gain." | 3.75 | Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. ( Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA, 2009) |
| " Efficacy of fenofibrate in subjects with moderate risk and type 2 diabetes combined with mild dyslipidemia was studied in the placebo controlled FIELD study." | 3.73 | [Expediency of the use of fibrates for primary and secondary prevention of cardiovascular complications.]. ( Mamedov, MN, 2006) |
| "The PPAR-gamma ligand rosiglitazone, but not the PPAR-alpha ligand fenofibrate, decreases intimal hyperplasia following balloon injury in both fatty and lean Zucker rats." | 3.72 | Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. ( Desouza, CV; Diez, J; Dunne, B; Fonseca, VA; Matta, AS; McNamara, DB; Murthy, SN, 2003) |
| "These findings suggest that pioglitazone and EPA may improve glucose tolerance by directly increasing hepatic insulin sensitivity, while fenofibrate may improve glucose tolerance by improving hepatic glycogen metabolism in the GK rats." | 3.72 | Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver. ( Horiike, N; Iwai, M; Kanno, S; Matsui, H; Matsuura, B; Minami, H; Onji, M; Tsubouchi, E, 2004) |
| "Fracture risk is elevated in some type 2 diabetes patients." | 3.30 | Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Center, JR; Colman, P; Drury, PL; Jenkins, AJ; Keech, AC; Kesäniemi, YA; Li, L; O'Brien, R; O'Connell, RL; Sheu, A; Sullivan, DR; Tran, T; White, CP, 2023) |
| "Fenofibrate was a cost-effective either as monotherapy or combined with a statin compared to statin or fenofibrate monotherapy." | 3.01 | A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. ( Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C, 2023) |
| "Fenofibrate treatment lowered the plasma C24:0/C16:0 ceramide ratio and minimally altered oxidative stress markers but did not alter measures of inflammation." | 2.94 | Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes. ( Chen, L; Farmer, MS; Goldberg, AC; Jiang, X; Ory, DS; Peterson, LR; Schaffer, JE, 2020) |
| "For patients with type 2 diabetes at high CV risk but no CKD, fenofibrate therapy added to statin reduced the CV mortality and the rate of fatal and non-fatal CHF." | 2.84 | Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. ( Applegate, WB; Cushman, W; Doumas, M; Lovato, L; Mottle, A; Nylen, E; Papademetriou, V; Punthakee, Z; Tsioufis, C, 2017) |
| "Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol." | 2.84 | Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. ( Buse, JB; Byington, RP; Corson, M; Elam, MB; Fleg, JL; Friedewald, WT; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, R; Ismail-Beigi, F; Largay, J; Leiter, LA; Lopez, C; Lovato, LC; O'Connor, PJ; Probstfield, J; Rosenberg, Y; Sweeney, ME; Weiss, D, 2017) |
| "Fenofibrate was shown to increase serum sirtuin 1 and decrease serum fetuin A levels in obese patients." | 2.80 | Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. ( Abd El-Razek, RS; El-Hefnawy, MH; El-Mesallamy, HO; Noureldein, MH, 2015) |
| "Treatment with fenofibrate significantly improved arterial endothelial function after 4 months." | 2.80 | Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. ( Celermajer, DS; Harmer, JA; Keech, AC; Marwick, TH; Meredith, IT; Skilton, MR; Veillard, AS; Watts, GF, 2015) |
| "ACCORD enrolled 10,251 type 2 diabetes patients aged 40-79 years at high risk for cardiovascular disease (CVD) events." | 2.79 | Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. ( Buse, JB; Cohen, RM; Cushman, WC; Cutler, JA; Evans, GW; Gerstein, HC; Goff, DC; Grimm, RH; Lipkin, EW; Margolis, KL; Morgan, TM; Narayan, KM; O'Connor, PJ; Riddle, MC; Sood, A, 2014) |
| "Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection." | 2.79 | Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Best, JD; d'Emden, MC; Jenkins, AJ; Keech, AC; Li, L; Mann, KP; Park, K; Saltevo, J; Stuckey, BG; Zannino, D, 2014) |
| "In adults with type 2 diabetes and known or suspected atherosclerosis, arterial smooth muscle-dependent dilatation was shown to be significantly impaired in cigarette smokers and those with elevated urinary albumin levels." | 2.79 | Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. ( Celermajer, DS; Harmer, JA; Keech, AC; Marwick, TH; Meredith, IT; Skilton, MR; Veillard, AS; Watts, GF, 2014) |
| "Depression has been identified as a risk factor for dementia among patients with type 2 diabetes mellitus but the cognitive domains and patient groups most affected have not been identified." | 2.78 | Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. ( Akpunonu, BE; Bryan, RN; Gerstein, HC; Horowitz, KR; Johnson, J; Katon, WJ; Launer, LJ; Lovato, LC; Marcovina, S; Miller, ME; Murray, AM; Sullivan, MD; Williamson, J; Yale, JF, 2013) |
| "Fenofibrate treatment should not be contraindicated in moderate renal impairment, suggesting that current guidelines may be too restrictive." | 2.77 | Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. ( Celermajer, D; Davis, TM; Donoghoe, MW; Drury, PL; Hedley, J; Jenkins, AJ; Keech, AC; Lehto, S; Rajamani, K; Simes, RJ; Stanton, K; Ting, RD, 2012) |
| "Fenofibrate has been noted to cause an elevation in serum creatinine in some individuals." | 2.77 | Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. ( Bonds, DE; Buse, J; Craven, TE; Crouse, JR; Cuddihy, R; Elam, M; Ginsberg, HN; Kirchner, K; Marcovina, S; Mychaleckyj, JC; O'Connor, PJ; Sperl-Hillen, JA, 2012) |
| "Fenofibrate treatment had no detectable effect on serum A-FABP level (P > 0." | 2.77 | Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. ( Barter, PJ; Brown, C; Jenkins, AJ; Keech, AC; O'Connell, R; Ong, KL; Rye, KA; Sullivan, DR; Xu, A, 2012) |
| "Twenty patients with type 2 diabetes and mixed hyperlipidemia were sequentially treated with simvastatin (20 mg/day) and fenofibrate (200 mg/day) in a randomized cross-over study (12 weeks each treatment)." | 2.77 | The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus. ( Ceska, R; Marinov, I; Skrha, J; Stulc, T, 2012) |
| "Patients with type 2 diabetes mellitus and mixed hyperlipidemia have an increased cardiovascular risk and may not achieve recommended LDL-C and non-HDL-C goals on statin monotherapy." | 2.76 | Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. ( Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A, 2011) |
| "Metformin-treated patients were likely to be younger, female, or obese." | 2.76 | Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. ( Colman, PG; Donoghoe, M; Forder, P; Graham, N; Haapamäki, H; Keech, A; Kritharides, L; Merrifield, A; Simes, J; Sullivan, D; Whiting, M, 2011) |
| "People with type 2 diabetes are at risk of cognitive impairment and brain atrophy." | 2.76 | Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. ( Bryan, RN; Coker, L; Davatzikos, C; Ding, J; Gerstein, HC; Hirsch, J; Horowitz, KR; Launer, LJ; Lazar, RM; Lipkin, EW; Lovato, J; Lovato, LC; Maldjian, J; Marcovina, S; Margolis, KL; Miller, ME; Murray, AM; O'Connor, P; Sullivan, M; Sunshine, JL; Truwit, C; Williamson, JD, 2011) |
| "Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an increased risk of cardiovascular disease (CVD) events." | 2.76 | Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. ( Colman, PG; Davis, TM; Donoghoe, M; Fulcher, G; Keech, AC; Manning, P; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Watts, GF, 2011) |
| "In patients with type 2 diabetes in the FIELD study, traditional lipid ratios were as strong as the ApoB:ApoA-I ratio in predicting CVD risk." | 2.75 | Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. ( Barter, PJ; Best, JD; Ehnholm, C; Hamwood, S; Keech, AC; Mann, K; Simes, J; Sullivan, DR; Taskinen, MR, 2010) |
| "Treatment with fenofibrate was associated with a lower risk of amputations, particularly minor amputations without known large-vessel disease, probably through non-lipid mechanisms." | 2.74 | Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. ( Baker, JR; Best, JD; Colman, PG; D'Emden, MC; Keech, AC; Laakso, M; Li, LP; Rajamani, K; Voysey, M, 2009) |
| " An unusual dose-response pattern was observed in that at 6 mg/day CP-778,875 only increased HDL cholesterol by 3% and decreased HDL(2) cholesterol by 24%." | 2.73 | Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. ( Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG, 2008) |
| "Treatment with fenofibrate did reduce all cardiovascular disease (CVD) events, the secondary end point (by 11%, p = 0." | 2.73 | After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. ( Sacks, FM, 2008) |
| "Fenofibrate treatment decreased serum triglyceride concentrations, while both blood glucose and glycated hemoglobin increased after three months of fenofibrate administration." | 2.73 | Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. ( Anderlová, K; Bosanská, L; Dolezalová, R; Haluzík, M; Haluzíková, D; Housová, J; Kremen, J; Skrha, J, 2007) |
| "In patients with type 2 diabetes and mixed hyperlipoproteinaemia, short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin, ghrelin or resistin levels." | 2.73 | Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. ( Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M, 2007) |
| "Most patients with type 2 diabetes mellitus develop cardiovascular disease (CVD), with substantial loss of life expectancy." | 2.73 | Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. ( Bigger, JT; Buse, JB; Byington, RP; Cooper, LS; Cushman, WC; Friedewald, WT; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Grimm, RH; Margolis, KL; Probstfield, JL; Simons-Morton, DG; Sullivan, MD, 2007) |
| "Fenofibrate caused an increase in LDL size (Delta 0." | 2.73 | Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. ( Ehnholm, C; Hiukka, A; Jauhiainen, M; Keech, AC; Leinonen, E; Sundvall, J; Taskinen, MR, 2007) |
| "Patients with type 2 diabetes mellitus and no histories of coronary heart disease were evaluated (n = 498)." | 2.73 | Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). ( Anderson, JL; Horne, BD; Jensen, JR; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Yannicelli, HD, 2008) |
| "Eighteen patients with hyperlipidemia and type 2 diabetes mellitus." | 2.72 | Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus. ( Asano, A; Inazu, A; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Murase, Y; Nohara, A; Shimizu, M, 2006) |
| "Insulin resistance was assessed by the homeostasis model." | 2.71 | Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. ( Hiukka, A; Hultén, LM; Hurt-Camejo, E; Leinonen, E; Taskinen, MR; Wiklund, O, 2003) |
| "A total of 418 subjects with type 2 diabetes were randomly assigned to 200 mg micronized fenofibrate daily or placebo." | 2.71 | Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Aubin, F; Foucher, C; Hamsten, A; Rattier, S; Steiner, G; Taskinen, MR; Vakkilainen, J, 2003) |
| "Disease progression is associated with variation in AAT, and low AAT levels promote atherogenesis." | 2.71 | Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. ( Flavell, DM; Frick, MH; Humphries, SE; Jackson, R; Kesäniemi, YA; Martin, S; Nagl, S; Nieminen, MS; Pasternack, A; Steiner, G; Syvänne, M; Talmud, PJ; Taskinen, MR; Whitehouse, DB, 2003) |
| "Patients with IHD and combined hyperlipidemia with (n=56)) or without type 2 diabetes (n=30)." | 2.71 | [Combination therapy with fluvastatin and fenofibrate in ischemic heart disease patients with combined hyperlipidemia and type 2 diabetes]. ( Kozlov, SG; Liakishev, AA; Naumov, VG; Sarano, NE; Tvorogova, MG, 2003) |
| "Twenty Type 2 diabetic patients with dyslipidemia were treated 3 months with simvastatin (20 mg daily) and then 3 months with fenofibrate (200 mg daily) with 2 months of wash-out between the two treatments." | 2.71 | Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. ( Ceska, R; Hilgertová, J; Kvasnicka, J; Skrha, J; Stulc, T; Weiserová, H, 2004) |
| "Fenofibrate was associated with less albuminuria progression (p=0." | 2.71 | Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. ( Barter, P; Best, J; Colman, P; d'Emden, M; Davis, T; Drury, P; Ehnholm, C; Forder, P; Glasziou, P; Hunt, D; Keech, A; Kesäniemi, YA; Laakso, M; Pillai, A; Scott, R; Simes, RJ; Sullivan, D; Taskinen, MR; Whiting, M, 2005) |
| "24 patients with type 2 diabetes, who after the combined hypolipidemic treatment (pravastatin 20 mg + micronized fenofibrate 200 mg per day) cannot reach the recommended target values for long time, received for three consecutive months supplementation of 3,6 g PUFA n-3 per day or a placebo (olive oil)." | 2.71 | [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination]. ( Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M, 2005) |
| "731 men and women with type 2 diabetes were screened by metabolic and angiographic criteria." | 2.70 | Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. ( , 2001) |
| "The incidence of coronary artery disease is greatly increased in those with diabetes mellitus." | 2.68 | The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. ( Steiner, G, 1996) |
| "Statins have a primary role in the treatment of dyslipidemia in people with type 2 diabetes, defined as triglyceride levels >200 mg/dl and HDL cholesterol levels <40 mg/dL." | 2.55 | Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. ( Anabtawi, A; Miles, JM; Moriarty, PM, 2017) |
| "Diabetic retinopathy is a significant cause of vision impairment, especially affecting those of working age." | 2.52 | The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. ( Newman, D; Ong, J; Ooi, JL; Sharma, N, 2015) |
| "Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α." | 2.47 | Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. ( Keating, GM, 2011) |
| "Diabetic retinopathy was associated with ∼ 1." | 2.47 | Does microvascular disease predict macrovascular events in type 2 diabetes? ( Dodson, PM; Fioretto, P; Rosenson, RS, 2011) |
| "Low HDL-C levels are common in type 2 diabetes but are not currently recommended as a target for treatment because of the lack of definitive cardiovascular outcome studies supporting this goal, and because of the difficulty in raising HDL-C." | 2.46 | Management of dyslipidemia in people with type 2 diabetes mellitus. ( Dunn, FL, 2010) |
| "Dyslipidemia is an important modifiable risk factor." | 2.46 | The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. ( Campbell, J; Mohiuddin, SM, 2010) |
| "Patients with type 2 diabetes or metabolic syndrome remain at high residual risk of cardiovascular events even after intensive statin therapy." | 2.45 | Combination statin-fibrate therapy: safety aspects. ( Franssen, R; Kastelein, JJ; Stroes, ES; Vergeer, M, 2009) |
| "Fenofibrate was generally well tolerated alone or in combination with a statin." | 2.45 | More clinical lessons from the FIELD study. ( Fazio, S, 2009) |
| "Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease." | 2.44 | Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. ( Brown, WV, 2008) |
| "Fenofibrate also has a favorable impact on a number of nonlipid residual risk factors associated with type 2 diabetes and metabolic syndrome, mediated by peroxisome proliferator-activated receptor-alpha." | 2.44 | Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. ( Steiner, G, 2008) |
| "Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures." | 2.44 | Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. ( Croom, KF; Keating, GM, 2007) |
| "The metabolic syndrome and type 2 diabetes mellitus are both becoming more prevalent, and both increase the risk of cardiovascular disease." | 2.43 | Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. ( Nesto, RW, 2005) |
| " Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| "Fenofibrate is a reasonable second-line therapy for dyslipidaemia in diabetes and safe in combination therapy." | 2.43 | FIELDS of dreams, fields of tears: a perspective on the fibrate trials. ( Wierzbicki, AS, 2006) |
| "Fenofibrate treatment was associated with less albuminuria progression and less retinopathy needing laser treatment." | 2.43 | Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. ( Vergès, B, 2006) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| " Recently, a new tablet formulation of micronised fenofibrate has become available with greater bioavailability than the older capsule formulation." | 2.41 | Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. ( Keating, GM; Ormrod, D, 2002) |
| "Fenofibrate has favorable pleiotropic effects on several features of the metabolic syndrome, which are likely to explain the clinical benefits of fibrate therapy, beyond an impact on HDL-C levels." | 2.41 | Increasing high-density lipoprotein cholesterol: an update on fenofibrate. ( Després, JP, 2001) |
| "Type 2 diabetes is associated with a marked increase in the risk of coronary artery disease." | 2.40 | Diabetes, hyperlipidemia, and coronary artery disease. ( Haffner, SM, 1999) |
| "Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis." | 1.72 | Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. ( Falcão-Pires, I; Ferrão, D; Ferreira, JP; Leite-Moreira, A; Neves, JS; Rossignol, P; Saraiva, F; Sharma, A; Vasques-Nóvoa, F; Zannad, F, 2022) |
| "Individuals with type 2 diabetes (T2D) and dyslipidemia are at an increased risk of cardiovascular disease." | 1.48 | Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. ( Buse, JB; Doria, A; Gao, H; Ginsberg, HN; Graf, GA; Havener, TM; Jack, JR; Marvel, SW; McLeod, HL; Morieri, ML; Motsinger-Reif, AA; Mychaleckyi, JC; Pijut, SS; Pujol, A; Rotroff, DM; Schluter, A; Shah, HS; Wagner, MJ, 2018) |
| "Fenofibrate was not associated with improved carotid IMT in adults with type 2 diabetes when compared with placebo, despite a statistically significant improvement in TC, LDL-C and TG at 2 and 4 years, and HDL-C at 4 months and 2 years." | 1.48 | Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy. ( Celermajer, DS; Harmer, JA; Keech, AC; Skilton, MR; Veillard, AS; Watts, GF, 2018) |
| "Fifty patients with type 2 diabetes, treated with statins, were selected and divided into two groups." | 1.46 | The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. ( Arimura, A; Arimura, H; Deguchi, T; Hashiguchi, H; Kikuti, A; Kurano, M; Nishio, Y; Shinnakasu, A; Yamamoto, K, 2017) |
| "This study reports this relationship in type 2 diabetes patients participating in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial." | 1.46 | Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. ( Barter, PJ; Best, JD; Colman, PG; Januszewski, AS; Jenkins, AJ; Keech, AC; O'Connell, R; Ong, KL; Rye, KA; Scott, RS; Simes, JR; Sullivan, DR; Taskinen, MR; Waldman, B; Xu, A, 2017) |
| " Dynamic observation of certain ophthalmologic (visual acuity, macular thickness zone) and system functional parameters (lipid fractions content in serum) in long-term use of this medical drug in 20 patients with diabetes type 2 and DMO for 8 months." | 1.46 | [CHANGES OF LIFETIME MORPHOLOGICAL PARAMETERS OF THE RETINA ON THE BACKGROUND OF CORRECTION OF LIPID METABOLISM IN PATIENTSWITH TYPE 2 DIABETES MELLITUS]. ( Veselovskaya, NN, 2017) |
| "Fenofibrate treatment partially reverses dyslipidemia in these subjects." | 1.43 | Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. ( Ginsberg, H; He, Y; Heinecke, JW; Oda, M; Reyes-Soffer, G; Ronsein, GE, 2016) |
| "Multifactorial diseases such as type 2 diabetes mellitus (T2DM), are driven by a complex network of interconnected mechanisms that translate to a diverse range of complications at the physiological level." | 1.40 | Network signatures link hepatic effects of anti-diabetic interventions with systemic disease parameters. ( Kelder, T; Radonjic, M; van Gool, AJ; van Ommen, B; Verschuren, L, 2014) |
| "Hypertriglyceridemia is an important and under-diagnosed etiology of acute non-biliary pancreatitis." | 1.39 | An acute edematous pancreatitis case developed on the basis of hypertriglyceridemia. ( Aslan, T; Aykas, F; Erden, A; Karagoz, H; Karahan, S; Karaman, A; Mutlu, H; Uslu, E, 2013) |
| "Bilirubin has antioxidant and anti-inflammatory activities." | 1.39 | Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Chan, KH; Donoghoe, MW; Hamer, A; Hoffmann, LS; Keech, AC; Ng, MK; O'Connell, RL; Rajamani, K; Stocker, R; Sullivan, DR; Vanhala, M; Whiting, M; Yu, B, 2013) |
| "Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia." | 1.38 | Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, MF; Erkoc, R; Soyoral, YU, 2012) |
| " After establishing a dose-response curve for each drug, the drugs were orally administered for 3 weeks either alone or in combination." | 1.37 | Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice. ( Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY, 2011) |
| "The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-alpha agonist fenofibrate (n=11 for T2DM)." | 1.37 | Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. ( Drápalová, J; Haluzík, M; Haluzíková, D; Hanušová, V; Kaválková, P; Lacinová, Z; Mráz, M; Trachta, P, 2011) |
| "In patients with type 2 diabetes, a subgroup analysis of a placebo-controlled trial of fenofibrate showed a significant decline in calculated creatinine clearance with fenofibrate." | 1.37 | Fenofibrate: altered renal function. ( , 2011) |
| "Fenofibrate has been evaluated in the ACCORD trial, in combination with a statin, to prevent vascular complications in patients with type 2 diabetes." | 1.36 | [Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes]. ( Scheen, AJ; Van Gaal, LF, 2010) |
| "The animal models of type 2 diabetes are very complex and are as heterogeneous as the disease." | 1.35 | Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes. ( Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A, 2008) |
| "Fenofibrate treatment resulted in normalization of abnormal lipid profiles and a reduction in Fb level." | 1.35 | Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes. ( Bukowska, H; Chełstowski, K; Jastrzebska, M; Klimek, K; Mierzecki, A, 2009) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 1.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| "Primary hypothyroidism and type 2 diabetes are both typically associated with the increased level of triglycerides." | 1.33 | A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas. ( Chang, SH; Chung, SI; Hahm, JR; Jung, JH; Jung, TS; Kim, DR; Kim, MA; Lee, GW; Park, JR; Park, KJ, 2005) |
| "The prognosis of the patients with the Type II diabetes mellitus without myocardial infarction is as serious as the prognosis of the patients who had experienced myocardial infarction without diabetes mellitus." | 1.33 | [The FIELD study presented and published. Unconvincing results of fenofibrates in diabetic patients]. ( Widimský, J, 2006) |
| "Treatment with fenofibrate or metformin ameliorated renal damage in OLETF rats through SREBP-1 and some enzyme regulated by it reduced fat deposit in kidney directly." | 1.33 | [Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney]. ( Guo, XH; Wang, NH; Wang, W; Wu, HH; Xu, XS, 2006) |
| "Fenofibrate treatment dramatically reduced fasting blood glucose (P<0." | 1.33 | PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. ( Breyer, M; Cha, DR; Chen, L; Davis, L; Fan, X; Guan, Y; Hwang, MT; Park, CW; Striker, G; Su, D; Wu, J; Zhang, X; Zhang, Y; Zheng, F, 2006) |
| "Fenofibrate treatment decreased body weight and visceral fat, whereas rosiglitazone treatment increased body weight." | 1.32 | Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. ( Kim, HS; Kim, MS; Koh, EH; Lee, KU; Park, HS; Park, JY; Youn, JH; Youn, JY, 2003) |
| "Fenofibrate increase mitochondrial fatty acid beta-oxidation in liver but not in skeletal muscle and lower the plasma levels of triglyceride and free fatty acid." | 1.31 | Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. ( An, YJ; Choi, SS; Garber, AJ; Hong, SH; Hwang, TH; Kang, DY; Kim, DK; Kim, MC; Lee, HJ; Park, MK; Seo, SY, 2002) |
| "The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes." | 1.31 | Status report of lipid-lowering trials in diabetes. ( Armitage, J; Betteridge, DJ; Colhoun, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.59) | 18.7374 |
| 1990's | 8 (2.37) | 18.2507 |
| 2000's | 150 (44.51) | 29.6817 |
| 2010's | 141 (41.84) | 24.3611 |
| 2020's | 36 (10.68) | 2.80 |
| Authors | Studies |
|---|---|
| Koyama, H | 1 |
| Miller, DJ | 1 |
| Boueres, JK | 1 |
| Desai, RC | 1 |
| Jones, AB | 2 |
| Berger, JP | 4 |
| MacNaul, KL | 2 |
| Kelly, LJ | 1 |
| Doebber, TW | 3 |
| Wu, MS | 1 |
| Zhou, G | 2 |
| Wang, PR | 1 |
| Ippolito, MC | 1 |
| Chao, YS | 2 |
| Agrawal, AK | 1 |
| Franklin, R | 1 |
| Heck, JV | 2 |
| Wright, SD | 2 |
| Moller, DE | 3 |
| Sahoo, SP | 1 |
| Henke, BR | 1 |
| Shi, GQ | 1 |
| Dropinski, JF | 1 |
| McKeever, BM | 1 |
| Xu, S | 1 |
| Becker, JW | 1 |
| Elbrecht, A | 1 |
| Wang, P | 1 |
| Forrest, M | 1 |
| Aoki, T | 1 |
| Asaki, T | 1 |
| Hamamoto, T | 1 |
| Sugiyama, Y | 1 |
| Ohmachi, S | 1 |
| Kuwabara, K | 1 |
| Murakami, K | 1 |
| Todo, M | 1 |
| Acton, JJ | 1 |
| Akiyama, TE | 2 |
| Chang, CH | 2 |
| Colwell, L | 1 |
| Debenham, S | 1 |
| Doebber, T | 1 |
| Einstein, M | 2 |
| Liu, K | 2 |
| McCann, ME | 2 |
| Muise, ES | 1 |
| Tan, Y | 2 |
| Thompson, JR | 1 |
| Wong, KK | 1 |
| Wu, M | 1 |
| Xu, L | 1 |
| Meinke, PT | 2 |
| Wood, HB | 2 |
| Liu, W | 1 |
| Gao, Q | 1 |
| Hanh, J | 1 |
| Váradi, L | 1 |
| Cairns, R | 1 |
| Sjöström, H | 1 |
| Liao, VW | 1 |
| Wood, P | 1 |
| Balaban, S | 1 |
| Ong, JA | 1 |
| Lin, HY | 1 |
| Lai, F | 1 |
| Hoy, AJ | 1 |
| Grewal, T | 1 |
| Groundwater, PW | 1 |
| Hibbs, DE | 1 |
| Sblano, S | 1 |
| Cerchia, C | 1 |
| Laghezza, A | 1 |
| Piemontese, L | 1 |
| Brunetti, L | 1 |
| Leuci, R | 1 |
| Gilardi, F | 1 |
| Thomas, A | 1 |
| Genovese, M | 1 |
| Santi, A | 1 |
| Tortorella, P | 1 |
| Paoli, P | 1 |
| Lavecchia, A | 1 |
| Loiodice, F | 1 |
| Zhang, X | 3 |
| Chen, Y | 1 |
| Tong, N | 1 |
| Shao, Q | 1 |
| Zhou, Y | 1 |
| Mu, T | 1 |
| Yang, X | 1 |
| Zhang, Y | 4 |
| Januszewski, AS | 10 |
| Chen, D | 1 |
| Scott, RS | 7 |
| O'Connell, RL | 8 |
| Aryal, NR | 1 |
| Sullivan, DR | 16 |
| Watts, GF | 13 |
| Taskinen, MR | 25 |
| Barter, PJ | 7 |
| Best, JD | 8 |
| Simes, RJ | 6 |
| Keech, AC | 34 |
| Jenkins, AJ | 21 |
| Warren, RA | 1 |
| Carew, AS | 1 |
| Andreou, P | 1 |
| Herman, C | 1 |
| Levy, AP | 1 |
| Ginsberg, HN | 12 |
| Sapp, J | 1 |
| Rimm, EB | 1 |
| Kirkland, S | 1 |
| Cahill, LE | 1 |
| Sheng, CS | 1 |
| Miao, Y | 1 |
| Ding, L | 2 |
| Cheng, Y | 1 |
| Wang, D | 1 |
| Yang, Y | 1 |
| Tian, J | 1 |
| Rao, BN | 1 |
| Quinn, N | 2 |
| Peto, T | 2 |
| Brazionis, L | 3 |
| Aryal, N | 4 |
| Li, L | 6 |
| Summanen, P | 1 |
| Scott, R | 8 |
| O'Day, J | 4 |
| Ferreira, JP | 1 |
| Vasques-Nóvoa, F | 1 |
| Ferrão, D | 1 |
| Saraiva, F | 1 |
| Falcão-Pires, I | 1 |
| Neves, JS | 1 |
| Sharma, A | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| Leite-Moreira, A | 1 |
| Meer, E | 1 |
| Bavinger, JC | 1 |
| Yu, Y | 1 |
| VanderBeek, BL | 1 |
| Frank, RN | 2 |
| O'Connell, R | 7 |
| Mitchell, P | 6 |
| Abushanab, D | 1 |
| Al-Badriyeh, D | 1 |
| Marquina, C | 1 |
| Bailey, C | 1 |
| Jaam, M | 1 |
| Liew, D | 1 |
| Ademi, Z | 1 |
| Honda, A | 1 |
| Kamata, S | 1 |
| Akahane, M | 1 |
| Machida, Y | 1 |
| Uchii, K | 1 |
| Shiiyama, Y | 1 |
| Habu, Y | 1 |
| Miyawaki, S | 1 |
| Kaneko, C | 1 |
| Oyama, T | 1 |
| Ishii, I | 1 |
| Hernandez-Arroyo, CF | 1 |
| Kanduri, SR | 1 |
| Justiniano, R | 1 |
| Martinez-Pitre, PJ | 1 |
| Velez, JCQ | 1 |
| Morieri, ML | 3 |
| van Walree, ES | 1 |
| Jansen, IE | 1 |
| Bell, NY | 1 |
| Savage, JE | 1 |
| de Leeuw, C | 1 |
| Nieuwdorp, M | 2 |
| van der Sluis, S | 1 |
| Posthuma, D | 1 |
| Teo, CHY | 3 |
| Lin, MT | 3 |
| Lee, IXY | 3 |
| Koh, SK | 3 |
| Zhou, L | 3 |
| Goh, DS | 3 |
| Choi, H | 3 |
| Koh, HWL | 3 |
| Lam, AYR | 3 |
| Lim, PS | 3 |
| Mehta, JS | 3 |
| Kovalik, JP | 3 |
| Coffman, TM | 3 |
| Tan, HC | 3 |
| Liu, YC | 3 |
| Kim, NH | 2 |
| Choi, J | 1 |
| Kim, YH | 1 |
| Lee, H | 1 |
| Kim, SG | 2 |
| O'Rourke, MB | 1 |
| Lengyel, I | 1 |
| Stewart, AJ | 1 |
| Arya, S | 1 |
| Ma, RC | 1 |
| Galande, S | 1 |
| Hardikar, AA | 1 |
| Joglekar, MV | 1 |
| Molloy, MP | 1 |
| Sheu, A | 1 |
| Tran, T | 1 |
| Drury, PL | 4 |
| Colman, P | 3 |
| O'Brien, R | 5 |
| Kesäniemi, YA | 7 |
| Center, JR | 1 |
| White, CP | 1 |
| Dong, L | 1 |
| Cheng, R | 2 |
| Ma, X | 1 |
| Liang, W | 1 |
| Hong, Y | 1 |
| Li, H | 2 |
| Zhou, K | 1 |
| Du, Y | 1 |
| Takahashi, Y | 2 |
| Li, XR | 1 |
| Ma, JX | 2 |
| Kataoka, SY | 1 |
| Lois, N | 1 |
| Kawano, S | 1 |
| Kataoka, Y | 1 |
| Inoue, K | 1 |
| Watanabe, N | 1 |
| Simó, R | 6 |
| Hernández, C | 4 |
| Tanaka, S | 1 |
| Brookhart, MA | 1 |
| Fine, J | 1 |
| Rao, B | 1 |
| Shimmin, G | 1 |
| Colman, PG | 6 |
| Chauhan, K | 1 |
| Nadkarni, GN | 1 |
| Debnath, N | 1 |
| Chan, L | 1 |
| Saha, A | 1 |
| Garg, AX | 1 |
| Parikh, CR | 1 |
| Coca, SG | 1 |
| Fruchart, JC | 3 |
| Santos, RD | 1 |
| Yamashita, S | 2 |
| Masuda, D | 1 |
| Matsuzawa, Y | 1 |
| Zhu, L | 1 |
| Hayen, A | 1 |
| Bell, KJL | 1 |
| Cao, JY | 1 |
| Waldman, B | 4 |
| Gebski, V | 2 |
| Marschner, I | 1 |
| Simes, JR | 2 |
| McGill, N | 2 |
| Smith, LB | 1 |
| Desai, NR | 1 |
| Dowd, B | 1 |
| Everhart, A | 1 |
| Herrin, J | 1 |
| Higuera, L | 1 |
| Jeffery, MM | 1 |
| Jena, AB | 1 |
| Ross, JS | 2 |
| Shah, ND | 1 |
| Karaca-Mandic, P | 1 |
| Peterson, LR | 1 |
| Jiang, X | 1 |
| Chen, L | 3 |
| Goldberg, AC | 1 |
| Farmer, MS | 1 |
| Ory, DS | 1 |
| Schaffer, JE | 1 |
| Sun, X | 2 |
| Liu, J | 1 |
| Wang, G | 3 |
| Lin, YC | 1 |
| Chen, YC | 1 |
| Horng, JT | 1 |
| Chen, JM | 1 |
| Ong, KL | 5 |
| Wu, L | 1 |
| Xu, A | 5 |
| Rye, KA | 6 |
| Ma, RCW | 1 |
| Jia, W | 2 |
| Heffernan, KS | 1 |
| Ranadive, SM | 1 |
| Jae, SY | 1 |
| Tang, Y | 1 |
| Shah, H | 1 |
| Bueno Junior, CR | 1 |
| Mitri, J | 1 |
| Sambataro, M | 1 |
| Sambado, L | 1 |
| Gerstein, HC | 10 |
| Fonseca, V | 1 |
| Doria, A | 3 |
| Pop-Busui, R | 1 |
| Davis, TME | 2 |
| Jo, SH | 1 |
| Nam, H | 1 |
| Lee, J | 2 |
| Park, S | 1 |
| Kyoung, DS | 1 |
| Shinnakasu, A | 1 |
| Yamamoto, K | 1 |
| Kurano, M | 1 |
| Arimura, H | 1 |
| Arimura, A | 1 |
| Kikuti, A | 1 |
| Hashiguchi, H | 1 |
| Deguchi, T | 1 |
| Nishio, Y | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Kalyani, RR | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Croyal, M | 1 |
| Kaabia, Z | 1 |
| León, L | 1 |
| Ramin-Mangata, S | 1 |
| Baty, T | 1 |
| Fall, F | 1 |
| Billon-Crossouard, S | 1 |
| Aguesse, A | 1 |
| Hollstein, T | 1 |
| Nobecourt, E | 1 |
| Lambert, G | 2 |
| Krempf, M | 1 |
| Anabtawi, A | 1 |
| Moriarty, PM | 1 |
| Miles, JM | 1 |
| Rotroff, DM | 2 |
| Pijut, SS | 1 |
| Marvel, SW | 1 |
| Jack, JR | 1 |
| Havener, TM | 1 |
| Pujol, A | 1 |
| Schluter, A | 1 |
| Graf, GA | 1 |
| Shah, HS | 2 |
| Gao, H | 2 |
| Mychaleckyi, JC | 1 |
| McLeod, HL | 1 |
| Buse, JB | 8 |
| Wagner, MJ | 2 |
| Motsinger-Reif, AA | 2 |
| Ju, HB | 1 |
| Zhang, FX | 1 |
| Wang, S | 1 |
| Song, J | 1 |
| Cui, T | 1 |
| Li, LF | 1 |
| Zhang, HY | 1 |
| Xie, Y | 1 |
| Xu, Y | 2 |
| Chen, Z | 1 |
| Lu, W | 1 |
| Li, N | 1 |
| Wang, Q | 1 |
| Shao, L | 1 |
| Li, Y | 1 |
| Yang, G | 1 |
| Bian, X | 1 |
| Shi, T | 1 |
| Lu, K | 1 |
| Shen, S | 1 |
| Tang, Q | 1 |
| Zhang, K | 1 |
| Zhu, X | 1 |
| Shi, Y | 1 |
| Liu, X | 1 |
| Teng, H | 1 |
| Li, C | 1 |
| Xue, B | 1 |
| Jiang, Q | 1 |
| Koopal, C | 1 |
| Visseren, FLJ | 1 |
| Westerink, J | 1 |
| van der Graaf, Y | 1 |
| Ansquer, JC | 9 |
| Buizen, L | 3 |
| Feher, MD | 1 |
| Foucher, C | 6 |
| Flack, J | 2 |
| d'Emden, MC | 4 |
| Hedley, J | 2 |
| Shi, R | 1 |
| Zhao, L | 1 |
| Qi, Y | 1 |
| Harmer, JA | 3 |
| Veillard, AS | 4 |
| Skilton, MR | 3 |
| Celermajer, DS | 3 |
| Veselovskaya, NN | 1 |
| Pigeyre, M | 1 |
| Sjaarda, J | 1 |
| Mendonca, C | 1 |
| Hastings, T | 1 |
| Buranasupkajorn, P | 1 |
| Sigal, RJ | 2 |
| Marcovina, SM | 1 |
| Kraft, P | 1 |
| Mychaleckyj, JC | 3 |
| Parè, G | 1 |
| Mottl, AK | 1 |
| Ismail-Beigi, F | 5 |
| Pedley, CF | 1 |
| Papademetriou, V | 3 |
| Simmons, DL | 2 |
| Katz, L | 1 |
| Craven, TE | 2 |
| Beddhu, S | 1 |
| Chertow, GM | 1 |
| Greene, T | 1 |
| Whelton, PK | 1 |
| Ambrosius, WT | 3 |
| Cheung, AK | 1 |
| Cutler, J | 1 |
| Fine, L | 1 |
| Boucher, R | 1 |
| Wei, G | 1 |
| Zhang, C | 1 |
| Kramer, H | 1 |
| Bress, AP | 1 |
| Kimmel, PL | 1 |
| Oparil, S | 1 |
| Lewis, CE | 1 |
| Rahman, M | 1 |
| Cushman, WC | 6 |
| Bosevski, M | 1 |
| Krstevski, G | 1 |
| Mitevska, I | 1 |
| Antova, E | 1 |
| Bosevska, G | 1 |
| Scheen, AJ | 3 |
| Wallemacq, C | 1 |
| De Flines, J | 1 |
| Paquot, N | 1 |
| Kalra, S | 1 |
| Sahay, R | 1 |
| Roy, S | 1 |
| Behar-Cohen, F | 1 |
| Keech, A | 6 |
| Wong, TY | 3 |
| Soyoral, YU | 1 |
| Canbaz, ET | 1 |
| Erdur, MF | 1 |
| Emre, H | 1 |
| Begenik, H | 1 |
| Erkoc, R | 1 |
| Sullivan, MD | 2 |
| Katon, WJ | 1 |
| Lovato, LC | 7 |
| Miller, ME | 2 |
| Murray, AM | 2 |
| Horowitz, KR | 2 |
| Bryan, RN | 2 |
| Marcovina, S | 3 |
| Akpunonu, BE | 1 |
| Johnson, J | 1 |
| Yale, JF | 1 |
| Williamson, J | 1 |
| Launer, LJ | 2 |
| Kavalkova, P | 2 |
| Touskova, V | 1 |
| Roubicek, T | 1 |
| Trachta, P | 2 |
| Urbanova, M | 1 |
| Drapalova, J | 2 |
| Haluzikova, D | 5 |
| Mraz, M | 3 |
| Novak, D | 1 |
| Matoulek, M | 2 |
| Lacinova, Z | 3 |
| Haluzik, M | 5 |
| Tsimihodimos, V | 1 |
| Mikhailidis, DP | 3 |
| Elisaf, M | 2 |
| Linz, PE | 2 |
| Byington, RP | 5 |
| O'Connor, PJ | 5 |
| Leiter, LA | 5 |
| Weiss, D | 3 |
| Force, RW | 1 |
| Crouse, JR | 4 |
| Elam, MB | 5 |
| Aslan, T | 1 |
| Erden, A | 1 |
| Karagoz, H | 1 |
| Karahan, S | 1 |
| Aykas, F | 1 |
| Uslu, E | 1 |
| Mutlu, H | 1 |
| Karaman, A | 1 |
| Margolis, KL | 4 |
| Morgan, TM | 1 |
| Cohen, RM | 1 |
| Cutler, JA | 1 |
| Evans, GW | 1 |
| Grimm, RH | 3 |
| Lipkin, EW | 2 |
| Narayan, KM | 1 |
| Riddle, MC | 1 |
| Sood, A | 1 |
| Goff, DC | 7 |
| Zhao, X | 2 |
| Leander, M | 1 |
| Emmett, N | 1 |
| Davis, TM | 9 |
| Gebski, VJ | 3 |
| Ng, MK | 2 |
| Li, J | 1 |
| Bi, L | 1 |
| Hulke, M | 1 |
| Li, T | 1 |
| Bogdanov, P | 1 |
| Corraliza, L | 1 |
| Carvalho, AR | 1 |
| Hu, Y | 1 |
| Humphries, KM | 1 |
| Gu, X | 1 |
| Elliott, MH | 1 |
| Xia, X | 1 |
| Massin, P | 1 |
| Aubonnet, P | 2 |
| MacuFEN Study Investigators, FT | 1 |
| Zannino, D | 4 |
| Mann, KP | 1 |
| Stuckey, BG | 2 |
| Park, K | 1 |
| Saltevo, J | 1 |
| Chew, EY | 2 |
| Davis, MD | 2 |
| Danis, RP | 2 |
| Lovato, JF | 2 |
| Perdue, LH | 2 |
| Greven, C | 1 |
| Genuth, S | 4 |
| Kelder, T | 1 |
| Verschuren, L | 1 |
| van Ommen, B | 1 |
| van Gool, AJ | 1 |
| Radonjic, M | 1 |
| Marwick, TH | 2 |
| Meredith, IT | 2 |
| Hung, WT | 1 |
| Masana, L | 2 |
| Cabré, A | 1 |
| Heras, M | 2 |
| Amigó, N | 2 |
| Correig, X | 2 |
| Martínez-Hervás, S | 2 |
| Real, JT | 1 |
| Ascaso, JF | 1 |
| Quesada, H | 1 |
| Julve, J | 1 |
| Palomer, X | 1 |
| Vázquez-Carrera, M | 1 |
| Girona, J | 1 |
| Plana, N | 2 |
| Blanco-Vaca, F | 1 |
| Kusunoki, M | 1 |
| Sato, D | 1 |
| Tsutsumi, K | 1 |
| Tsutsui, H | 1 |
| Nakamura, T | 1 |
| Oshida, Y | 1 |
| Noureldein, MH | 1 |
| Abd El-Razek, RS | 1 |
| El-Hefnawy, MH | 1 |
| El-Mesallamy, HO | 1 |
| Krysiak, R | 4 |
| Gdula-Dymek, A | 3 |
| Marek, B | 2 |
| Okopień, B | 5 |
| Sharma, N | 1 |
| Ooi, JL | 1 |
| Ong, J | 1 |
| Newman, D | 1 |
| Aguiar, C | 1 |
| Alegria, E | 1 |
| Bonadonna, RC | 1 |
| Catapano, AL | 1 |
| Cosentino, F | 1 |
| Farnier, M | 3 |
| Ferrières, J | 1 |
| Filardi, PP | 1 |
| Hancu, N | 1 |
| Kayikcioglu, M | 1 |
| Mello E Silva, A | 1 |
| Millan, J | 1 |
| Reiner, Ž | 1 |
| Tokgozoglu, L | 1 |
| Valensi, P | 1 |
| Viigimaa, M | 1 |
| Vrablik, M | 2 |
| Zambon, A | 2 |
| Zamorano, JL | 1 |
| Ferrari, R | 1 |
| Williams, KH | 2 |
| George, J | 2 |
| Young, S | 2 |
| Ehnholm, C | 8 |
| Duffield, A | 1 |
| Twigg, SM | 2 |
| Shih, CC | 1 |
| Wu, JB | 1 |
| Jian, JY | 1 |
| Lin, CH | 1 |
| Ho, HY | 1 |
| Rosolová, H | 1 |
| Ronsein, GE | 1 |
| Reyes-Soffer, G | 1 |
| He, Y | 1 |
| Oda, M | 1 |
| Ginsberg, H | 2 |
| Heinecke, JW | 1 |
| Mallol, R | 1 |
| Blanco Vaca, F | 1 |
| Escolà-Gil, JC | 1 |
| Yanes, Ó | 1 |
| Tsunoda, F | 1 |
| Asztalos, IB | 1 |
| Horvath, KV | 1 |
| Steiner, G | 12 |
| Schaefer, EJ | 1 |
| Asztalos, BF | 1 |
| Feng, X | 1 |
| Gao, X | 2 |
| Jia, Y | 1 |
| Zhang, H | 1 |
| Béliard-Lasserre, S | 1 |
| Nicholson, GC | 1 |
| Manning, P | 2 |
| Tan, YM | 1 |
| Donoghoe, MW | 4 |
| Márk, L | 1 |
| Dani, G | 1 |
| Czupryniak, L | 1 |
| Joshi, SR | 1 |
| Gogtay, JA | 1 |
| Lopez, M | 1 |
| Mandala, A | 1 |
| Das, N | 1 |
| Bhattacharjee, S | 1 |
| Mukherjee, B | 1 |
| Mukhopadhyay, S | 1 |
| Roy, SS | 1 |
| Lovato, L | 1 |
| Tsioufis, C | 1 |
| Cushman, W | 1 |
| Applegate, WB | 1 |
| Mottle, A | 1 |
| Punthakee, Z | 1 |
| Nylen, E | 1 |
| Doumas, M | 1 |
| Farris, RA | 1 |
| Price, ET | 1 |
| Corson, M | 1 |
| Largay, J | 1 |
| Lopez, C | 1 |
| Sweeney, ME | 1 |
| Friedewald, WT | 3 |
| Probstfield, J | 2 |
| Grimm, R | 1 |
| Fleg, JL | 2 |
| Rosenberg, Y | 1 |
| Franssen, R | 1 |
| Vergeer, M | 1 |
| Stroes, ES | 2 |
| Kastelein, JJ | 3 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Terra, SG | 1 |
| Francone, OL | 1 |
| Contant, CF | 1 |
| Lewin, AJ | 1 |
| Nguyen, TT | 1 |
| Arulmozhi, DK | 1 |
| Kurian, R | 1 |
| Bodhankar, SL | 1 |
| Veeranjaneyulu, A | 1 |
| Fulcher, G | 2 |
| Pardy, C | 3 |
| D'Emden, M | 2 |
| Tse, D | 2 |
| Sacks, FM | 3 |
| Brown, WV | 1 |
| Jones, PH | 2 |
| Wu, H | 1 |
| Wei, L | 1 |
| Bao, Y | 1 |
| Lu, J | 1 |
| Huang, P | 1 |
| Liu, Y | 1 |
| Xiang, K | 1 |
| Hiukka, A | 6 |
| Westerbacka, J | 1 |
| Leinonen, ES | 3 |
| Watanabe, H | 1 |
| Wiklund, O | 2 |
| Hulten, LM | 2 |
| Salonen, JT | 2 |
| Tuomainen, TP | 1 |
| Yki-Järvinen, H | 1 |
| Clarke, PM | 1 |
| Hayes, AJ | 1 |
| Glasziou, PG | 1 |
| Simes, J | 4 |
| Fazio, S | 2 |
| Le Malicot, K | 1 |
| Fernandes-Santos, C | 1 |
| Evangelista Carneiro, R | 1 |
| de Souza Mendonca, L | 1 |
| Barbosa Aguila, M | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Polenova, NV | 1 |
| Vaulin, NA | 1 |
| Masenko, VP | 1 |
| Iavelov, IS | 1 |
| Gratsianskiĭ, NA | 1 |
| Cetinkaya, R | 1 |
| Uyanik, A | 1 |
| Yildirim, R | 1 |
| Bilen, Y | 1 |
| Keles, M | 1 |
| Whiting, M | 5 |
| Lai, MY | 1 |
| Lin, CC | 1 |
| Chung, SL | 1 |
| Wu, CH | 1 |
| Yang, WC | 1 |
| Tseng, YT | 1 |
| Jastrzebska, M | 1 |
| Chełstowski, K | 1 |
| Mierzecki, A | 1 |
| Klimek, K | 1 |
| Bukowska, H | 1 |
| Pruski, M | 1 |
| Linton, MF | 1 |
| Rajamani, K | 3 |
| Li, LP | 1 |
| Voysey, M | 1 |
| Laakso, M | 4 |
| Baker, JR | 1 |
| Toth, PP | 1 |
| Derosa, G | 2 |
| Maffioli, P | 1 |
| Salvadeo, SA | 1 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Mereu, R | 1 |
| Palumbo, I | 1 |
| D'Angelo, A | 1 |
| Cicero, AF | 1 |
| Unnikrishnan, R | 1 |
| Das, R | 1 |
| Jaydip, R | 1 |
| Sudhakaran, C | 1 |
| Mohan, V | 1 |
| Bartlova, M | 1 |
| Michalsky, D | 1 |
| Kasalicky, M | 1 |
| Dostalova, I | 1 |
| Humenanska, V | 1 |
| Burgess, DC | 1 |
| Hunt, D | 2 |
| Williamson, E | 2 |
| Zhang, J | 1 |
| Sy, RW | 1 |
| Lehto, S | 2 |
| Mann, S | 1 |
| Forsblom, C | 1 |
| Sundvall, J | 3 |
| Groop, PH | 1 |
| Hamilton, SJ | 2 |
| Chew, GT | 4 |
| Cusi, K | 2 |
| Davidson, MH | 2 |
| Kelly, MT | 2 |
| Setze, CM | 2 |
| Thakker, K | 1 |
| Sleep, DJ | 1 |
| Stolzenbach, JC | 2 |
| Im, M | 1 |
| Kim, M | 1 |
| Lee, JK | 1 |
| Chang, YH | 1 |
| Lee, DY | 1 |
| Hong, SI | 1 |
| Lee, YY | 1 |
| Hong, YJ | 1 |
| Dunn, FL | 1 |
| Nilsson, PM | 1 |
| Linz, P | 1 |
| Bigger, JT | 2 |
| Simons-Morton, DG | 3 |
| Kraja, AT | 1 |
| Province, MA | 1 |
| Straka, RJ | 1 |
| Ordovas, JM | 1 |
| Borecki, IB | 1 |
| Arnett, DK | 1 |
| Hahm, JR | 2 |
| Ahn, JS | 1 |
| Noh, HS | 1 |
| Baek, SM | 1 |
| Ha, JH | 1 |
| Jung, TS | 2 |
| An, YJ | 2 |
| Kim, DK | 2 |
| Kim, DR | 2 |
| Mann, K | 1 |
| Hamwood, S | 1 |
| Tenenbaum, A | 2 |
| Fisman, EZ | 2 |
| Klein, BE | 1 |
| Gangaputra, S | 1 |
| Greven, CM | 1 |
| Hubbard, L | 1 |
| Esser, BA | 1 |
| Schubart, U | 1 |
| Fine, LJ | 1 |
| Ruiz, J | 2 |
| Egli, M | 1 |
| Gianinazzi, F | 1 |
| Izzo, F | 1 |
| Voeffray Favre, AC | 1 |
| Rossi, I | 1 |
| Bodenman, P | 1 |
| Costet, P | 1 |
| Hoffmann, MM | 1 |
| Cariou, B | 1 |
| Guyomarc'h Delasalle, B | 1 |
| Konrad, T | 1 |
| Winkler, K | 1 |
| Chan, DC | 2 |
| Ting, R | 2 |
| Fassett, R | 1 |
| Dixon, P | 1 |
| Maeda, T | 1 |
| Oyama, J | 1 |
| Higuchi, Y | 1 |
| Koyanagi, M | 1 |
| Sasaki, M | 1 |
| Arima, T | 1 |
| Mimori, K | 1 |
| Makino, N | 1 |
| Pérez, A | 1 |
| Saely, CH | 1 |
| Rein, P | 1 |
| Drexel, H | 1 |
| Tonkin, AM | 1 |
| Tkacheva, ON | 1 |
| Sharashkina, NV | 1 |
| Novikova, IM | 1 |
| Torshkhoeva, KhM | 1 |
| Carey, VJ | 1 |
| Perkins, WJ | 1 |
| Whiting, MJ | 1 |
| Glasziou, PP | 1 |
| Campbell, J | 1 |
| Mohiuddin, SM | 1 |
| Van Gaal, LF | 1 |
| Elam, M | 2 |
| Giral, P | 1 |
| Rosenbaum, D | 1 |
| Baum, SJ | 1 |
| Liew, G | 2 |
| Wang, JJ | 2 |
| Siegel, D | 1 |
| Swislocki, AL | 1 |
| Rosenson, RS | 3 |
| Carlson, DM | 1 |
| Hirshberg, B | 1 |
| Williams, LA | 1 |
| Udani, SM | 1 |
| Bakris, GL | 1 |
| Kishimoto, M | 1 |
| Sugiyama, T | 1 |
| Osame, K | 1 |
| Takarabe, D | 1 |
| Okamoto, M | 1 |
| Noda, M | 1 |
| Steinmetz, A | 2 |
| Retterstøl, K | 2 |
| Császár, A | 2 |
| Noguchi, T | 1 |
| Kobayashi, J | 2 |
| Yagi, K | 1 |
| Nohara, A | 2 |
| Yamaaki, N | 1 |
| Sugihara, M | 1 |
| Ito, N | 1 |
| Oka, R | 1 |
| Kawashiri, MA | 2 |
| Tada, H | 1 |
| Takata, M | 1 |
| Inazu, A | 2 |
| Yamagishi, M | 1 |
| Mabuchi, H | 2 |
| Jackevicius, CA | 1 |
| Tu, JV | 1 |
| Ko, DT | 1 |
| Carreon, D | 1 |
| Krumholz, HM | 1 |
| Wright, AD | 1 |
| Dodson, PM | 2 |
| Egan, A | 1 |
| Byrne, M | 1 |
| Choi, WS | 1 |
| Lee, JJ | 1 |
| Kim, Y | 1 |
| Kim, IS | 1 |
| Zhang, WY | 1 |
| Myung, CS | 1 |
| Hanušová, V | 1 |
| Ai, M | 1 |
| Yoshida, M | 1 |
| Keating, GM | 3 |
| Maranghi, M | 1 |
| Badeau, R | 1 |
| Jauhiainen, M | 2 |
| Lim, LS | 1 |
| Fioretto, P | 1 |
| Goldfine, AB | 1 |
| Kaul, S | 1 |
| Hiatt, WR | 1 |
| Sullivan, D | 2 |
| Forder, P | 3 |
| Kritharides, L | 1 |
| Merrifield, A | 2 |
| Donoghoe, M | 2 |
| Graham, N | 1 |
| Haapamäki, H | 1 |
| Liamina, NP | 1 |
| Karpova, ÉS | 1 |
| Kotel'nikova, EV | 1 |
| Nosenko, AN | 1 |
| Susekov, AV | 1 |
| Khokhlova, NV | 1 |
| Williamson, JD | 1 |
| Lazar, RM | 1 |
| Sullivan, M | 1 |
| Ding, J | 1 |
| Lovato, J | 1 |
| O'Connor, P | 1 |
| Hirsch, J | 1 |
| Coker, L | 1 |
| Maldjian, J | 1 |
| Sunshine, JL | 1 |
| Truwit, C | 1 |
| Davatzikos, C | 1 |
| Balakumar, P | 1 |
| Jagadeesh, G | 1 |
| Ting, RD | 1 |
| Celermajer, D | 1 |
| Stanton, K | 1 |
| Schäfer, HL | 1 |
| Linz, W | 1 |
| Falk, E | 1 |
| Glien, M | 1 |
| Glombik, H | 1 |
| Korn, M | 1 |
| Wendler, W | 1 |
| Herling, AW | 1 |
| Rütten, H | 1 |
| Rosenblit, PD | 1 |
| Wong, AT | 1 |
| Lewis, D | 1 |
| Wanner, C | 1 |
| Rehman, HU | 1 |
| Bonds, DE | 2 |
| Buse, J | 1 |
| Cuddihy, R | 1 |
| Kirchner, K | 1 |
| Sperl-Hillen, JA | 1 |
| Brown, C | 1 |
| Stulc, T | 3 |
| Ceska, R | 3 |
| Marinov, I | 1 |
| Skrha, J | 4 |
| Chan, KH | 1 |
| Hoffmann, LS | 1 |
| Vanhala, M | 1 |
| Hamer, A | 1 |
| Yu, B | 1 |
| Stocker, R | 1 |
| Glineur, C | 1 |
| Gross, B | 1 |
| Neve, B | 1 |
| Rommens, C | 1 |
| Martin-Nizard, F | 1 |
| Rodríguez-Pascual, F | 1 |
| Lamas, S | 1 |
| Staels, B | 1 |
| Katsiki, N | 1 |
| Karagiannis, A | 1 |
| Lee, HJ | 1 |
| Choi, SS | 1 |
| Park, MK | 1 |
| Seo, SY | 1 |
| Kim, MC | 1 |
| Hong, SH | 1 |
| Hwang, TH | 1 |
| Kang, DY | 1 |
| Garber, AJ | 1 |
| Ormrod, D | 1 |
| Salonen, RM | 1 |
| Koistinen, RA | 1 |
| Leinonen, PJ | 1 |
| Sarna, SS | 1 |
| Hodgson, JM | 1 |
| Playford, DA | 3 |
| Burke, V | 4 |
| Croft, KD | 2 |
| Forcheron, F | 1 |
| Cachefo, A | 1 |
| Thevenon, S | 1 |
| Pinteur, C | 1 |
| Beylot, M | 1 |
| Cavallero, E | 2 |
| Dachet, C | 1 |
| Assadolahi, F | 1 |
| Martin, C | 1 |
| Navarro, N | 1 |
| Corda, C | 1 |
| Juhan-Vague, I | 1 |
| Jacotot, B | 2 |
| Leinonen, E | 3 |
| Hurt-Camejo, E | 1 |
| Vakkilainen, J | 2 |
| Aubin, F | 1 |
| Rattier, S | 3 |
| Hamsten, A | 1 |
| Talmud, PJ | 2 |
| Martin, S | 1 |
| Flavell, DM | 2 |
| Whitehouse, DB | 1 |
| Nagl, S | 1 |
| Jackson, R | 1 |
| Frick, MH | 1 |
| Nieminen, MS | 1 |
| Pasternack, A | 1 |
| Humphries, SE | 2 |
| Syvänne, M | 1 |
| Jokinen, V | 1 |
| Ukkola, O | 1 |
| Airaksinen, KE | 1 |
| Koistinen, JM | 1 |
| Ikäheimo, MJ | 1 |
| Huikuri, HV | 1 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 2 |
| Tuomilehto, J | 2 |
| Barker, BJ | 1 |
| Goodenough, RR | 1 |
| Sarano, NE | 1 |
| Kozlov, SG | 1 |
| Tvorogova, MG | 1 |
| Liakishev, AA | 1 |
| Naumov, VG | 1 |
| Koh, EH | 1 |
| Kim, MS | 1 |
| Park, JY | 1 |
| Kim, HS | 1 |
| Youn, JY | 1 |
| Park, HS | 1 |
| Youn, JH | 1 |
| Lee, KU | 1 |
| Wierzbicki, AS | 2 |
| Wray, R | 1 |
| Desouza, CV | 1 |
| Murthy, SN | 1 |
| Diez, J | 1 |
| Dunne, B | 1 |
| Matta, AS | 1 |
| Fonseca, VA | 1 |
| McNamara, DB | 1 |
| Genest, J | 1 |
| Frohlich, J | 2 |
| Durrington, PN | 1 |
| Hamann, A | 1 |
| Kallend, D | 1 |
| Smith, K | 1 |
| Wysocki, J | 1 |
| Belowski, D | 1 |
| Kalina, M | 1 |
| Kochanski, L | 1 |
| Kalina, Z | 1 |
| Matsuura, B | 1 |
| Kanno, S | 1 |
| Minami, H | 1 |
| Tsubouchi, E | 1 |
| Iwai, M | 1 |
| Matsui, H | 1 |
| Horiike, N | 1 |
| Onji, M | 1 |
| Hilgertová, J | 2 |
| Weiserová, H | 1 |
| Kvasnicka, J | 1 |
| Iglesias, P | 1 |
| Alvarez Fidalgo, P | 1 |
| Codoceo, R | 1 |
| Díez, JJ | 1 |
| Dobordzhginidze, LM | 1 |
| Cicero, AE | 1 |
| Bertone, G | 1 |
| Piccinni, MN | 1 |
| Ciccarelli, L | 1 |
| Roggeri, DE | 1 |
| Ayyobi, A | 1 |
| Pimstone, S | 1 |
| Reifel-Miller, A | 1 |
| Otto, K | 1 |
| Hawkins, E | 1 |
| Barr, R | 1 |
| Bensch, WR | 1 |
| Bull, C | 1 |
| Dana, S | 1 |
| Klausing, K | 1 |
| Martin, JA | 1 |
| Rafaeloff-Phail, R | 1 |
| Rafizadeh-Montrose, C | 1 |
| Rhodes, G | 1 |
| Robey, R | 1 |
| Rojo, I | 1 |
| Rungta, D | 1 |
| Snyder, D | 1 |
| Wilbur, K | 1 |
| Zhang, T | 1 |
| Zink, R | 1 |
| Warshawsky, A | 1 |
| Brozinick, JT | 1 |
| Jacob, SS | 1 |
| Jacob, S | 1 |
| Williams, C | 1 |
| Deeg, MA | 1 |
| Fruchart-Najib, J | 1 |
| Hilden, H | 1 |
| Park, JR | 1 |
| Jung, JH | 1 |
| Lee, GW | 1 |
| Kim, MA | 1 |
| Park, KJ | 1 |
| Chang, SH | 1 |
| Chung, SI | 1 |
| Seber, S | 1 |
| Ucak, S | 1 |
| Basat, O | 1 |
| Altuntas, Y | 1 |
| Wu, KK | 1 |
| Wu, TJ | 2 |
| Chin, J | 1 |
| Mitnaul, LJ | 1 |
| Hernandez, M | 1 |
| Cai, TQ | 1 |
| Ren, N | 1 |
| Waters, MG | 1 |
| Cheng, K | 1 |
| Best, J | 2 |
| Barter, P | 2 |
| Ledl, M | 1 |
| Hohenecker, J | 1 |
| Francesconi, C | 1 |
| Roots, I | 1 |
| Bauer, MF | 1 |
| Roden, M | 1 |
| Choi, KC | 1 |
| Ryu, OH | 1 |
| Lee, KW | 1 |
| Kim, HY | 1 |
| Seo, JA | 1 |
| Choi, DS | 1 |
| Baik, SH | 1 |
| Choi, KM | 1 |
| Nesto, RW | 1 |
| Colhoun, H | 2 |
| Pillai, A | 1 |
| Davis, T | 1 |
| Glasziou, P | 1 |
| Drury, P | 1 |
| Zeman, M | 2 |
| Zák, A | 2 |
| Vecka, M | 2 |
| Tvrzická, E | 2 |
| Písaríková, A | 1 |
| Stanková, B | 2 |
| Fegan, PG | 1 |
| Shore, AC | 1 |
| Mawson, D | 1 |
| Tooke, JE | 1 |
| MacLeod, KM | 1 |
| Bailey, CJ | 1 |
| Radermecker, RP | 1 |
| Letonturier, P | 1 |
| Widimský, J | 1 |
| Asano, A | 1 |
| Murase, Y | 1 |
| Shimizu, M | 1 |
| Sirtori, CR | 1 |
| Föger, B | 1 |
| Wang, W | 2 |
| Guo, XH | 2 |
| Wu, HH | 1 |
| Wang, NH | 2 |
| Xu, XS | 1 |
| Varghese, Z | 1 |
| Moorhead, JF | 1 |
| Ruan, XZ | 1 |
| Park, CW | 1 |
| Wu, J | 1 |
| Cha, DR | 1 |
| Su, D | 1 |
| Hwang, MT | 1 |
| Fan, X | 1 |
| Davis, L | 1 |
| Striker, G | 1 |
| Zheng, F | 1 |
| Breyer, M | 1 |
| Guan, Y | 1 |
| Rees, A | 1 |
| Reasner, CA | 1 |
| Muhlestein, JB | 2 |
| May, HT | 2 |
| Jensen, JR | 2 |
| Horne, BD | 2 |
| Lanman, RB | 1 |
| Lavasani, F | 2 |
| Wolfert, RL | 1 |
| Pearson, RR | 2 |
| Yannicelli, HD | 2 |
| Anderson, JL | 2 |
| Iovine, C | 1 |
| Lilli, S | 1 |
| Gentile, A | 1 |
| Patti, L | 1 |
| Di Marino, L | 1 |
| Cipriano, P | 1 |
| Riccardi, G | 1 |
| Rivellese, AA | 1 |
| Usman, M | 1 |
| Peter, R | 1 |
| Meas, T | 1 |
| Cimadevilla, C | 1 |
| Timsit, J | 1 |
| Mouly, S | 1 |
| Guillausseau, PJ | 1 |
| Vergès, B | 1 |
| Anderlová, K | 2 |
| Dolezalová, R | 3 |
| Housová, J | 2 |
| Bosanská, L | 1 |
| Kremen, J | 1 |
| Boden, G | 1 |
| Homko, C | 1 |
| Mozzoli, M | 1 |
| Zhang, M | 1 |
| Kresge, K | 1 |
| Cheung, P | 1 |
| Croom, KF | 1 |
| Xie, W | 1 |
| Nie, Y | 1 |
| Du, L | 1 |
| Cai, G | 1 |
| Mamedov, MN | 1 |
| Otsuki, M | 1 |
| Goya, K | 1 |
| Kasayama, S | 1 |
| Stopka, P | 1 |
| Zahin, M | 1 |
| Vareka, T | 1 |
| Janíková, L | 1 |
| Stroup, JS | 1 |
| Karalliedde, J | 1 |
| Viberti, GC | 1 |
| Bajaj, M | 1 |
| Suraamornkul, S | 1 |
| Hardies, LJ | 1 |
| Glass, L | 1 |
| Musi, N | 1 |
| DeFronzo, RA | 1 |
| Ou, HY | 1 |
| Chou, CW | 1 |
| Hsiao, SH | 1 |
| Lin, CY | 1 |
| Kao, PC | 1 |
| Otto, C | 2 |
| Otto, B | 1 |
| Frost, RJ | 2 |
| Vogeser, M | 1 |
| Pfeiffer, AF | 1 |
| Spranger, J | 1 |
| Parhofer, KG | 2 |
| Carrington, M | 1 |
| Stewart, S | 1 |
| Tokuno, A | 1 |
| Hirano, T | 1 |
| Hayashi, T | 1 |
| Mori, Y | 1 |
| Yamamoto, T | 1 |
| Nagashima, M | 1 |
| Shiraishi, Y | 1 |
| Ito, Y | 1 |
| Adachi, M | 1 |
| Cooper, LS | 1 |
| Probstfield, JL | 2 |
| Lipkin, E | 1 |
| Benatar, JR | 1 |
| Stewart, RA | 1 |
| Plutzky, J | 1 |
| Tanabe, J | 1 |
| Tamasawa, N | 1 |
| Yamashita, M | 1 |
| Matsuki, K | 1 |
| Murakami, H | 1 |
| Matsui, J | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Suda, T | 1 |
| Summanen, PA | 1 |
| Moffitt, MS | 1 |
| Laatikainen, LT | 1 |
| Crimet, DC | 1 |
| Hogue, JC | 2 |
| Lamarche, B | 2 |
| Deshaies, Y | 1 |
| Tremblay, AJ | 2 |
| Bergeron, J | 2 |
| Gagné, C | 2 |
| Couture, P | 2 |
| Haluzík, MM | 1 |
| Adamíková, A | 1 |
| Svacina, S | 1 |
| Li, LY | 1 |
| Dobiásová, M | 1 |
| Kasalová, Z | 1 |
| Prázný, M | 1 |
| Fait, T | 1 |
| Gillies, M | 1 |
| Cannon, CP | 1 |
| Zhou, JY | 1 |
| Zhou, SW | 1 |
| Beilin, LJ | 1 |
| Thompson, PL | 1 |
| Currie, PJ | 1 |
| Piolot, A | 1 |
| Sindelka, G | 1 |
| Haas, T | 1 |
| Justová, V | 1 |
| McLaughlin, PR | 1 |
| Gladstone, P | 1 |
| Hall, RR | 1 |
| Haffner, SM | 1 |
| Stewart, D | 1 |
| Hosking, JD | 1 |
| Betteridge, DJ | 1 |
| Armitage, J | 1 |
| Geiss, HC | 1 |
| Schwandt, P | 1 |
| Tan, CE | 1 |
| Chew, LS | 1 |
| Tai, ES | 1 |
| Chio, LF | 1 |
| Lim, HS | 1 |
| Loh, LM | 1 |
| Shepherd, J | 1 |
| Milionis, HJ | 1 |
| Bairaktari, ET | 1 |
| Liberopoulos, EN | 1 |
| Elisaf, MS | 1 |
| Forster, T | 1 |
| Marx, N | 1 |
| Hombach, V | 1 |
| Després, JP | 1 |
| Perttunen-Nio, H | 1 |
| Athyros, VG | 1 |
| Papageorgiou, AA | 1 |
| Athyrou, VV | 1 |
| Demitriadis, DS | 1 |
| Kontopoulos, AG | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Hajós, P | 1 |
| Tornyossi, M | 1 |
| Smud, R | 1 |
| Sermukslis, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy[NCT02314533] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk Peopl[NCT00069784] | Phase 3 | 12,537 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Physiopathological Study of Genetic Modulation of Cardiovascular Effect of PPAR-Alpha Activation (MAGNETIC-PPARA)[NCT05542147] | 200 participants (Anticipated) | Interventional | 2022-07-03 | Recruiting | |||
| Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume: Assessments on Retinal Endothelial Vascular Dysfunction, Inflammation, and Angiogenesis in Diabetic Retinopathy With Dyslipidemia[NCT04885153] | 36 participants (Actual) | Interventional | 2016-11-01 | Completed | |||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study[NCT00542178] | Phase 3 | 3,472 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients[NCT02704468] | 100 participants (Actual) | Observational [Patient Registry] | 2016-01-31 | Completed | |||
| Comparison of the Effect of Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Treated With Glimepiride[NCT04528212] | Phase 4 | 60 participants (Actual) | Interventional | 2020-11-01 | Completed | ||
| Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients[NCT06155331] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-12-31 | Recruiting | ||
| Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Single Oral Tolvaptan Tablets on Hemodynamic Parameters in Subjects With Heart Failure[NCT00132886] | Phase 2 | 140 participants (Anticipated) | Interventional | 2004-12-31 | Completed | ||
| Association of Serum Fibroblast Growth Factor 21 (FGF-21) Levels With Resting Metabolic Rate (RMR), in Children and Adolescents With Hashimoto's Thyroiditis.[NCT02725879] | 60 participants (Anticipated) | Observational | 2016-03-31 | Recruiting | |||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300469] | Phase 3 | 613 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300482] | Phase 3 | 1,445 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 and Simvastatin Combination Therapy to ABT-335 and Simvastatin Monotherapy in Subjects With Mixed Dyslipidemia[NCT00300456] | Phase 3 | 657 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes[NCT04929379] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | ||
| A 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia[NCT00463606] | Phase 3 | 760 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| "FGF19 in Obstructive Cholestasis: Unveil the Signal"[NCT05718349] | 81 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis[NCT03507374] | Early Phase 1 | 20 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Funding withdrawn) | ||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study: A Randomized, Double-Blind Study of Simvastatin, Fenofibrate, and Combined Fenofibrate and Simvastatin in Patients With Controlled Type II Diabetics Without Evidence of Coronary Disease[NCT00309712] | 300 participants | Interventional | 2002-08-31 | Completed | |||
| Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP).[NCT04882293] | Phase 3 | 78 participants (Anticipated) | Interventional | 2022-02-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
The incidence was determined by calculating the proportion of randomized participants without diabetes at randomization who either developed diabetes during the study or who were classified as having possible diabetes based on results of two oral glucose tolerance tests (OGTT) performed after the last follow-up visit (within 21-28 days for OGTT#1 and within 10-14 weeks for OGTT#2). (NCT00069784)
Timeframe: from randomization until the last follow-up visit or last OGTT (median duration of follow-up: 6.2 years)
| Intervention | percentage of patients (Number) |
|---|---|
| Insulin Glargine | 24.7 |
| Standard Care | 31.2 |
Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee. (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) |
|---|---|
| Insulin Glargine | 559 |
| Standard Care | 561 |
Number of deaths due to any cause (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) |
|---|---|
| Insulin Glargine | 951 |
| Standard Care | 965 |
"The composite outcome used to analyze microvascular disease progression contained components of clinical events:~the occurrence of laser surgery or vitrectomy for diabetic retinopathy (DR);~the development of blindness due to DR;~the occurrence of renal death or renal replacement therapy; as well as the following laboratory-based events:~doubling of serum creatinine; or~progression of albuminuria (from none to microalbuminuria [at least 30 mg/g creatinine], to macroalbuminuria [at least 300 mg/g creatinine])." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: vitrectomy | Endpoint's composition: laser therapy for DR | Endpoint's composition: dialysis | Endpoint's composition: renal transplant | Endpoint's composition: serum creatinine doubled | Endpoint's composition: death due to renal failure | Endpoint's composition: albuminuria progression | |
| Insulin Glargine | 1323 | 24 | 57 | 18 | 0 | 82 | 4 | 1153 |
| Standard Care | 1363 | 25 | 67 | 28 | 0 | 88 | 3 | 1171 |
"Number of participants with a first occurrence of one of the above events.~The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.~Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of CV death, nonfatal MI or nonfatal stroke) is provided in the first row of the statistical table." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: CV death | Endpoint's composition: nonfatal MI | Endpoint's composition: nonfatal stroke | |
| Insulin Glargine | 1041 | 484 | 297 | 261 |
| Standard Care | 1013 | 476 | 282 | 256 |
"Number of participants with a first occurrence of one of the above events (revascularization procedures included coronary artery bypass graft, percutaneous transluminal coronary angioplasty (PTCA) i.e. balloon, PTCA with stent, other percutaneous intervention, carotid angioplasty with/without stent, carotid endarterectomy, peripheral angioplasty with or without stent, peripheral vascular surgery, and limb amputation due to vascular disease).~The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.~Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of the events) is provided in the first row of the statistical table." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: CV death | Endpoint's composition: nonfatal MI | Endpoint's composition: nonfatal stroke | Endpoint's composition: revascularization | Endpoint's composition: hospitalization for HF | |
| Insulin Glargine | 1792 | 350 | 257 | 231 | 763 | 249 |
| Standard Care | 1727 | 339 | 238 | 227 | 717 | 259 |
"Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia, based on data recorded in the participant's diary. These were further categorized as confirmed (ie, with a concomitant home glucose reading ≤54 mg/dL [≤3.0 mmol/L]) or unconfirmed.~Severe hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following:~the event was associated with a documented self-measured or laboratory plasma glucose level ≤36 mg/dL (≤2.0 mmol/L), or~the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration." (NCT00069784)
Timeframe: on-treatment period (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Patients with hypoglycemia events | Patients with non-severe hypoglycemia | Patients with confirmed non-severe hypoglycemia | Patients with severe hypoglycemia | |
| Insulin Glargine | 3597 | 3533 | 2581 | 352 |
| Standard Care | 1624 | 1582 | 904 | 113 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 547 |
| Standard Glycemia Control | 623 |
| Intensive Blood Pressure Control | 266 |
| Standard Blood Pressure Control | 300 |
| Fenofibrate + Simvastatin Therapy | 305 |
| Placebo + Simvastatin Therapy | 299 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 44 |
| Standard Glycemia Control | 40 |
| Intensive Blood Pressure Control | 18 |
| Standard Blood Pressure Control | 20 |
| Fenofibrate + Simvastatin Therapy | 24 |
| Placebo + Simvastatin Therapy | 22 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 744 |
| Standard Glycemia Control | 752 |
| Intensive Blood Pressure Control | 367 |
| Standard Blood Pressure Control | 382 |
| Fenofibrate + Simvastatin Therapy | 354 |
| Placebo + Simvastatin Therapy | 393 |
Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher. (NCT00542178)
Timeframe: Measured at Year 4
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemia Control | 104 |
| Standard Glycemia Control | 149 |
| Intensive Blood Pressure Control | 67 |
| Standard Blood Pressure Control | 54 |
| Fenofibrate + Simvastatin Therapy | 52 |
| Placebo + Simvastatin Therapy | 80 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | 14.0 |
| ABT-335 + 40 mg Atorvastatin | 12.6 |
| ABT-335 | 19.9 |
| 20 mg Atorvastatin | 6.3 |
| 40 mg Atorvastatin | 5.3 |
| 80 mg Atorvastatin | 6.2 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -37.0 |
| ABT-335 + 40 mg Atorvastatin | -37.1 |
| ABT-335 | -12.4 |
| 20 mg Atorvastatin | -32.9 |
| 40 mg Atorvastatin | -35.3 |
| 80 mg Atorvastatin | -40.3 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -33.7 |
| ABT-335 + 40 mg Atorvastatin | -35.4 |
| ABT-335 | -3.4 |
| 20 mg Atorvastatin | -37.1 |
| 40 mg Atorvastatin | -39.7 |
| 80 mg Atorvastatin | -46.0 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -40.8 |
| ABT-335 + 40 mg Atorvastatin | -42.5 |
| ABT-335 | -14.8 |
| 20 mg Atorvastatin | -35.7 |
| 40 mg Atorvastatin | -41.7 |
| 80 mg Atorvastatin | -45.2 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -32.8 |
| ABT-335 + 40 mg Atorvastatin | -34.6 |
| ABT-335 | -10.1 |
| 20 mg Atorvastatin | -29.6 |
| 40 mg Atorvastatin | -33.8 |
| 80 mg Atorvastatin | -38.2 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -45.6 |
| ABT-335 + 40 mg Atorvastatin | -42.1 |
| ABT-335 | -29.6 |
| 20 mg Atorvastatin | -16.5 |
| 40 mg Atorvastatin | -23.2 |
| 80 mg Atorvastatin | -30.4 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -48.3 |
| ABT-335 + 40 mg Atorvastatin | -53.5 |
| ABT-335 | -36.5 |
| 20 mg Atorvastatin | -26.2 |
| 40 mg Atorvastatin | -35.6 |
| 80 mg Atorvastatin | -38.9 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300469)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Atorvastatin | -26.2 |
| ABT-335 + 40 mg Atorvastatin | -42.9 |
| ABT-335 | -12.4 |
| 20 mg Atorvastatin | -29.6 |
| 40 mg Atorvastatin | -30.3 |
| 80 mg Atorvastatin | -31.9 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | 20.3 |
| ABT-335 + 20 mg Rosuvastatin | 19.0 |
| ABT-335 | 15.0 |
| 10 mg Rosuvastatin | 8.5 |
| 20 mg Rosuvastatin | 10.3 |
| 40 mg Rosuvastatin | 9.3 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -39.2 |
| ABT-335 + 20 mg Rosuvastatin | -39.2 |
| ABT-335 | -16.2 |
| 10 mg Rosuvastatin | -34.1 |
| 20 mg Rosuvastatin | -39.6 |
| 40 mg Rosuvastatin | -45.0 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -37.2 |
| ABT-335 + 20 mg Rosuvastatin | -38.8 |
| ABT-335 | -6.5 |
| 10 mg Rosuvastatin | -38.0 |
| 20 mg Rosuvastatin | -45.0 |
| 40 mg Rosuvastatin | -50.6 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -44.7 |
| ABT-335 + 20 mg Rosuvastatin | -45.3 |
| ABT-335 | -18.5 |
| 10 mg Rosuvastatin | -39.8 |
| 20 mg Rosuvastatin | -45.8 |
| 40 mg Rosuvastatin | -51.5 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -34.4 |
| ABT-335 + 20 mg Rosuvastatin | -35.7 |
| ABT-335 | -13.5 |
| 10 mg Rosuvastatin | -32.5 |
| 20 mg Rosuvastatin | -37.3 |
| 40 mg Rosuvastatin | -42.7 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -47.1 |
| ABT-335 + 20 mg Rosuvastatin | -42.9 |
| ABT-335 | -32.6 |
| 10 mg Rosuvastatin | -24.4 |
| 20 mg Rosuvastatin | -25.6 |
| 40 mg Rosuvastatin | -32.1 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -55.8 |
| ABT-335 + 20 mg Rosuvastatin | -50.6 |
| ABT-335 | -31.9 |
| 10 mg Rosuvastatin | -41.0 |
| 20 mg Rosuvastatin | -42.1 |
| 40 mg Rosuvastatin | -49.1 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300482)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 10 mg Rosuvastatin | -33.8 |
| ABT-335 + 20 mg Rosuvastatin | -40.8 |
| ABT-335 | -12.1 |
| 10 mg Rosuvastatin | -22.9 |
| 20 mg Rosuvastatin | -29.9 |
| 40 mg Rosuvastatin | -33.1 |
[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | 17.8 |
| ABT-335 + 40 mg Simvastatin | 18.9 |
| ABT-335 | 16.2 |
| 20 mg Simvastatin | 7.2 |
| 40 mg Simvastatin | 8.5 |
| 80 mg Simvastatin | 6.8 |
[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -29.5 |
| ABT-335 + 40 mg Simvastatin | -31.2 |
| ABT-335 | -17.6 |
| 20 mg Simvastatin | -22.9 |
| 40 mg Simvastatin | -32.7 |
| 80 mg Simvastatin | -38.9 |
[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -24.0 |
| ABT-335 + 40 mg Simvastatin | -25.3 |
| ABT-335 | -4.0 |
| 20 mg Simvastatin | -22.4 |
| 40 mg Simvastatin | -31.7 |
| 80 mg Simvastatin | -40.8 |
[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -30.7 |
| ABT-335 + 40 mg Simvastatin | -35.0 |
| ABT-335 | -17.3 |
| 20 mg Simvastatin | -24.4 |
| 40 mg Simvastatin | -35.9 |
| 80 mg Simvastatin | -40.6 |
[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -23.9 |
| ABT-335 + 40 mg Simvastatin | -27.1 |
| ABT-335 | -12.4 |
| 20 mg Simvastatin | -19.8 |
| 40 mg Simvastatin | -30.0 |
| 80 mg Simvastatin | -33.6 |
[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -37.4 |
| ABT-335 + 40 mg Simvastatin | -42.7 |
| ABT-335 | -31.7 |
| 20 mg Simvastatin | -14.2 |
| 40 mg Simvastatin | -22.4 |
| 80 mg Simvastatin | -20.2 |
[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -38.9 |
| ABT-335 + 40 mg Simvastatin | -51.1 |
| ABT-335 | -36.9 |
| 20 mg Simvastatin | -19.2 |
| 40 mg Simvastatin | -35.7 |
| 80 mg Simvastatin | -30.0 |
[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100 (NCT00300456)
Timeframe: Baseline to 12 Weeks (Final Visit)
| Intervention | percent change (Median) |
|---|---|
| ABT-335 + 20 mg Simvastatin | -26.8 |
| ABT-335 + 40 mg Simvastatin | -32.1 |
| ABT-335 | -15.8 |
| 20 mg Simvastatin | -11.4 |
| 40 mg Simvastatin | -14.8 |
| 80 mg Simvastatin | -19.8 |
The mean percent change from baseline to the final visit in apolipoprotein B (ApoB), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -30.9 |
| Rosuvastatin Calcium | -26.4 |
The mean percent change from baseline to the final visit in High-density lipoprotein cholesterol (HDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | 23.0 |
| Rosuvastatin Calcium | 12.4 |
The mean percent change from baseline to the final visit in low-density lipoprotein cholesterol (LDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus ABT-335 135 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -28.7 |
| ABT-335 | -4.1 |
The mean percent change from baseline to the final visit in non-high-density lipoprotein cholesterol (non-HDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus ABT-335 135 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -37.4 |
| ABT-335 | -16.0 |
The mean percent change from baseline to the final visit in non-high-density lipoprotein cholesterol (non-HDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -37.4 |
| Rosuvastatin Calcium | -31.8 |
The mean percent change from baseline to the final visit in total cholesterol, with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -28.1 |
| Rosuvastatin Calcium | -25.0 |
The mean percent change from baseline to the final visit in triglycerides, with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -40.3 |
| Rosuvastatin Calcium | -17.5 |
The mean percent change from baseline to the final visit in very-low-density lipoprotein cholesterol (VLDL-C), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Mean) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -41.3 |
| Rosuvastatin Calcium | -22.2 |
The median percent change from baseline to the final visit in high sensitivity C-reactive protein (hsCRP), with ABT-335 135 mg in combination with rosuvastatin 5 mg versus rosuvastatin 5 mg monotherapy. (NCT00463606)
Timeframe: Baseline to 12 Weeks
| Intervention | percent change (Median) |
|---|---|
| ABT-335 and Rosuvastatin Calcium | -28.0 |
| Rosuvastatin Calcium | -11.4 |
53 reviews available for fenofibrate and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; M | 2004 |
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; | 2023 |
Fenofibrate for diabetic retinopathy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Mac | 2023 |
SPPARM alpha: the Lazarus effect.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofib | 2019 |
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug | 2020 |
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptid | 2017 |
Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; | 2013 |
Summarizing the FIELD study: lessons from a 'negative' trial.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemi | 2013 |
The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review.
Topics: Australia; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans | 2015 |
[What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin].
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents | 2015 |
[Diabetic dyslipidaemia and the atherosclerosis].
Topics: Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins C; Atherosclerosis; Cardiovascular Diseases; | 2016 |
Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Disease Progression; Drug C | 2016 |
Combination statin-fibrate therapy: safety aspects.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2009 |
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dys | 2008 |
Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Fenofibrat | 2008 |
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug | 2008 |
More clinical lessons from the FIELD study.
Topics: Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; | 2009 |
Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2009 |
Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective.
Topics: Community Health Services; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combinati | 2009 |
Advances in the medical treatment of diabetic retinopathy.
Topics: Blindness; Blood-Retinal Barrier; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Dia | 2009 |
How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Topics: Albuminuria; Amputation, Surgical; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2009 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ez | 2010 |
Fenofibrate and metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hydroxymethylglu | 2010 |
Lipid disorders in type 2 diabetes.
Topics: Atherosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Hu | 2009 |
The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Topics: Choline; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; H | 2010 |
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fenofibrate; Humans; H | 2011 |
Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
Topics: Adult; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Glycate | 2011 |
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Fenofibrate; Humans; Hypol | 2011 |
Does microvascular disease predict macrovascular events in type 2 diabetes?
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Do | 2011 |
[Perspectives of the use of fenofibrate in patients with type 2 diabetes mellitus: what is new after the ACCORD Study?].
Topics: Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Human | 2011 |
Do persons with diabetes benefit from combination statin and fibrate therapy?
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Female; | 2012 |
Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipid | 2012 |
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Databases, Bibliographic; Diabetes Mellitus, Type 2; Drug Delivery Systems; | 2002 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2003 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
[Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Topics: Adult; Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2004 |
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents | 2005 |
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Drug T | 2005 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mell | 2006 |
FIELD study.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic | 2006 |
Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Homocysteine; Humans; Hypolipidemic | 2006 |
Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents; Metabolic Syndr | 2007 |
Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
Topics: Antihypertensive Agents; Atherosclerosis; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; | 2005 |
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofib | 2007 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Dia | 2007 |
Combination therapy in the management of mixed dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Routes; Dr | 2008 |
Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects.
Topics: Diabetes Mellitus, Type 2; Eating; Fenofibrate; Humans; Lipoproteins; Metabolic Clearance Rate | 1995 |
Diabetes, hyperlipidemia, and coronary artery disease.
Topics: Apolipoproteins B; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fenofibrat | 1999 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as To | 2001 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
126 trials available for fenofibrate and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Haptoglobins; Heart Disease Risk F | 2022 |
Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Adult; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fractures, Bone; Huma | 2023 |
G-estimation of structural nested mean models for interval-censored data using pseudo-observations.
Topics: Causality; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans | 2023 |
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Drug Therapy, | 2020 |
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Heart Disease Risk Factors; | 2020 |
Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes.
Topics: Adult; Ceramides; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heart; Humans; Male; Middle Aged; | 2020 |
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Gl | 2020 |
Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?
Topics: Aged; Biomarkers; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Female; Fenofibrate | 2018 |
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Gout; Humans; Hypolipidem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
Topics: Aged; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fem | 2018 |
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Ty | 2018 |
Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mell | 2018 |
Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial.
Topics: Cardiovascular Diseases; Cognition Disorders; Depression; Diabetes Mellitus, Type 2; Female; Fenofib | 2013 |
Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment.
Topics: Anthropometry; Body Weight; Calcium-Binding Proteins; Caloric Restriction; Diabetes Mellitus, Type 2 | 2013 |
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 2014 |
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dise | 2014 |
HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes.
Topics: Aged; Apolipoprotein A-I; Blood Glucose; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitu | 2014 |
Effects of fenofibric acid on diabetic macular edema: the MacuFen study.
Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Fema | 2014 |
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Melli | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy.
Topics: Aged; Albuminuria; Brachial Artery; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, V | 2014 |
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; | 2015 |
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
Black soybean extract improves lipid profiles in fenofibrate-treated type 2 diabetics with postprandial hyperlipidemia.
Topics: Adult; Aged; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Synergism; Female; Fen | 2015 |
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Topics: Aged; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Metho | 2015 |
Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis.
Topics: Aged; alpha-2-HS-Glycoprotein; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Fenofibrate; H | 2015 |
Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
Topics: Aged; Australia; Brachial Artery; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; End | 2015 |
Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Adult; Aged; Alanine Transaminase; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; F | 2016 |
Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Biomarkers; Blood Glucose; Canada; Card | 2016 |
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Alanine Transaminase; Australia; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofib | 2017 |
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2017 |
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; C-Reactive Protein; Cholesterol, HDL; Diabete | 2008 |
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypo | 2009 |
After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; D | 2008 |
Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue.
Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Adult; Animals; Diabetes Mellitus, Type 2; Down-Regulatio | 2009 |
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
Topics: Acute-Phase Proteins; Aged; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Artery Disease | 2008 |
Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes.
Topics: Aged; Algorithms; Australia; Cause of Death; Diabetes Complications; Diabetes Mellitus, Type 2; Fema | 2009 |
[Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibra | 2009 |
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Australia; Biomarkers; Cholesterol, HDL; Creatinine; Diabet | 2009 |
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Combined Modality Therapy; Cytokines; Di | 2009 |
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Topics: Age Distribution; Aged; Amputation, Surgical; Body Height; Cardiovascular Diseases; Diabetes Mellitu | 2009 |
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Fem | 2009 |
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Electrocardiography; Female; Fenofibrate; Fo | 2010 |
Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Female; Fen | 2010 |
Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.
Topics: Adult; Aged; Apolipoprotein B-100; Arterioles; Blood Glucose; Brachial Artery; Cholesterol, LDL; Cro | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Effects of combination lipid therapy in type 2 diabetes mellitus.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2010 |
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.
Topics: Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins B; Cardiovascular Di | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabe | 2010 |
Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2010 |
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.
Topics: Aged; Creatinine; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerular Filtration Rate; Humans | 2011 |
The ACCORD Study: the devil is in the details.
Topics: Blood Pressure; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2 | 2011 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, | 2011 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, | 2011 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, | 2011 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, | 2011 |
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug A | 2011 |
Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; Cholesterol; Diabetes Mellitus, Ty | 2011 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double | 2011 |
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adipokines; Adiponectin; Adult; Aged; Bezafibrate; Body Mass Index; Cho | 2011 |
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Male; Placebo Effect; Simvast | 2011 |
[Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Humans; Hypolipidemic Ag | 2010 |
Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Topics: Administration, Oral; Aged; Australia; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Me | 2011 |
[Possibilities of improvement of prognosis in patients with type 2 diabetes mellitus after coronary interventions].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Corona | 2011 |
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Brain; Cognition; Diabetes Mellitus, Type 2; | 2011 |
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Brain; Cognition; Diabetes Mellitus, Type 2; | 2011 |
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Brain; Cognition; Diabetes Mellitus, Type 2; | 2011 |
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Brain; Cognition; Diabetes Mellitus, Type 2; | 2011 |
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Topics: Aged; Australia; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Diabetes Mellitus, Type | 2011 |
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerular Filtration | 2012 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Ty | 2012 |
Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein B-48; Apolipoprotein C-III; Brachial Artery; Chole | 2012 |
Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.
Topics: Aged; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; H | 2012 |
Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Double-Blind Method; Female; Fenofibrate | 2012 |
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
Topics: Adult; CD11a Antigen; CD18 Antigens; Cross-Over Studies; Diabetes Mellitus, Type 2; Dyslipidemias; F | 2012 |
Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells.
Topics: Apoptosis Regulatory Proteins; Binding Sites; Brachial Artery; Cell Cycle Proteins; Cell Line; Diabe | 2013 |
Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes.
Topics: Aged; Carotid Arteries; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; | 2002 |
Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.
Topics: Antioxidants; Blood Glucose; Blood Pressure; Coenzymes; Diabetes Mellitus, Type 2; Dietary Supplemen | 2002 |
Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus.
Topics: Brachial Artery; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Feno | 2002 |
Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.
Topics: Adult; Apolipoproteins B; Biguanides; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Dietary Fats; Do | 2003 |
Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes.
Topics: Acute-Phase Reaction; Age Distribution; Aged; Analysis of Variance; Biomarkers; Blood Glucose; Body | 2003 |
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Adult; Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angi | 2003 |
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Topics: 3' Untranslated Regions; Aged; Alleles; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Amino A | 2003 |
Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes.
Topics: Acetylcholine; Antioxidants; Apolipoprotein A-I; Area Under Curve; Blood Circulation; Blood Pressure | 2003 |
Temporal changes in cardiovascular autonomic regulation in type II diabetic patients: association with coronary risk variables and progression of coronary artery disease.
Topics: Adult; Aged; Arteriosclerosis; Autonomic Nervous System; Coronary Angiography; Diabetes Mellitus, Ty | 2003 |
[Combination therapy with fluvastatin and fenofibrate in ischemic heart disease patients with combined hyperlipidemia and type 2 diabetes].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fem | 2003 |
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2004 |
Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Topics: Adult; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, | 2004 |
Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.
Topics: Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Insul | 2004 |
Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
Topics: Acetylglucosaminidase; Adult; Aged; alpha-Tocopherol; Ascorbic Acid; Cholesterol; Czech Republic; Di | 2004 |
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Coronary Disease; Delayed-Action Preparat | 2004 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellit | 2006 |
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Topics: Aged; Apolipoproteins B; Australia; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Choleste | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
[Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibra | 2005 |
Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.
Topics: Adult; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combi | 2005 |
[Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypoli | 2005 |
Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus.
Topics: Coenzymes; Diabetes Mellitus, Type 2; Disease Progression; Female; Fenofibrate; Humans; Hyperlipidem | 2006 |
Field of confusion: future prospects for fibrate therapy in cardiovascular disease.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Diabetes Mellitus, Type 2; Double-Blind | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Di | 2006 |
Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over | 2006 |
Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
Topics: Adipokines; Adiponectin; Adipose Tissue; Blood Glucose; Body Mass Index; Case-Control Studies; Chole | 2007 |
Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.
Topics: Adiponectin; Blood Glucose; Body Water; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty | 2007 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; F | 2006 |
Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Topics: Adiponectin; AMP-Activated Protein Kinases; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, | 2007 |
Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Topics: Atherosclerosis; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cholesterol; Diabetes Mellitus | 2007 |
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus | 2007 |
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofibrate; Glycated Hem | 2007 |
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofib | 2007 |
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Sched | 2007 |
Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrat | 2007 |
Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response R | 2007 |
Fenofibrate for diabetic retinopathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Follow-Up Studies; Humans; Hypolipidem | 2007 |
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Humans; Hypolipidemic Ag | 2007 |
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Atorvastatin; Cholesterol; Diab | 2008 |
Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Fatty A | 2009 |
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; H | 2008 |
Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Feno | 2008 |
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fe | 2008 |
Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diabe | 2008 |
The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group.
Topics: Adult; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; | 1996 |
Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis.
Topics: Adult; Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angi | 1998 |
Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Diseas | 1999 |
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies | 2001 |
Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Blood Glucose; Blood Pressure; Cholesterol | 2001 |
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.
Topics: Adult; Aged; Analysis of Variance; Angiography; Cholesterol; Coronary Artery Disease; Diabetes Melli | 2001 |
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
Topics: Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofibrate; H | 2002 |
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Ch | 2002 |
Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double- | 1987 |
159 other studies available for fenofibrate and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
Topics: Animals; Benzopyrans; Chromans; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Humans; Hypoglycemic Ag | 2004 |
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
Topics: Animals; Cricetinae; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dogs; Hypoglycemic Agents; H | 2005 |
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Humans; Hypogly | 2008 |
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus w
Topics: Animals; Blood Volume; Body Fluids; Diabetes Mellitus, Type 2; Dogs; Haplorhini; Humans; Hypoglycemi | 2009 |
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; | 2009 |
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
Topics: 3T3-L1 Cells; Animals; Cell Line; Diabetes Mellitus, Type 2; Drug Design; HEK293 Cells; Humans; Liga | 2015 |
A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
Topics: Cheminformatics; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands | 2022 |
Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report.
Topics: Atorvastatin; Bezafibrate; Deafness; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperli | 2022 |
Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorescent Dyes; Humans; Hypolipidemic | 2021 |
Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Female; F | 2022 |
Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Glycated Hemoglobin; Humans; Male; Ris | 2022 |
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glucose; Heart Failure; Hum | 2022 |
Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Humans; | 2022 |
Use of Fenofibrate in the Management of Diabetic Retinopathy-Large Population Analyses.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans | 2022 |
Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Retinal Vessels; Venules | 2022 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; | 2022 |
Improvement in Kidney Function after Discontinuation of Fenofibrate in Outpatient Nephrology Consultation for Chronic Kidney Disease.
Topics: Creatinine; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerular Filtration Rate; Humans; Kidn | 2022 |
Heart Failure Burden in Diabetes: Can Fenofibrate Provide Additional Hope?
Topics: Diabetes Mellitus, Type 2; Fenofibrate; Heart Failure; Humans; Hypolipidemic Agents | 2022 |
Disentangling Genetic Risks for Metabolic Syndrome.
Topics: Blood Glucose; Blood Pressure; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fenofibrate; Genome-Wide | 2022 |
Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes.
Topics: Cornea; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fenofibrate; Humans; Hypoglycemic Agents; | 2023 |
Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes.
Topics: Cornea; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fenofibrate; Humans; Hypoglycemic Agents; | 2023 |
Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes.
Topics: Cornea; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fenofibrate; Humans; Hypoglycemic Agents; | 2023 |
Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes.
Topics: Cornea; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fenofibrate; Humans; Hypoglycemic Agents; | 2023 |
Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Hydroxymethylg | 2023 |
Optimised plasma sample preparation and LC-MS analysis to support large-scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial.
Topics: Adult; Biomarkers; Blood Proteins; Chromatography, Liquid; Diabetes Mellitus, Type 2; Fenofibrate; H | 2023 |
Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Monocytes; Nucleotidyltransfe | 2023 |
Fenofibrate for Treating Diabetic Eye Disease.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Eye Diseases; Fenofibrate; Humans; Hypoglycemic A | 2023 |
No relationship between socioeconomic status, education level and development and progression of diabetic retinopathy in type 2 diabetes: a FIELD trial substudy.
Topics: Adult; Australia; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Educational Status; Fenofibrate; | 2023 |
The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypolipidemic Agents; Kidn | 2019 |
Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Databases, Factual; Diabetes M | 2020 |
Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fem | 2020 |
Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study.
Topics: Chronic Disease; Diabetes Mellitus, Type 2; Fatty Acid-Binding Proteins; Female; Fenofibrate; Humans | 2020 |
Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy.
Topics: Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytoplasm; | 2020 |
Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate | 2021 |
Fenofibrate and Impaired Taste Perception in Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Insulin; Taste; Taste Perception | 2020 |
Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fenofibrate; Humans; National He | 2021 |
The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes.
Topics: Anticholesteremic Agents; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimib | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.
Topics: Aged; Alanine Transaminase; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; | 2017 |
Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
Topics: Aldehyde Reductase; Animals; beta Karyopherins; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fe | 2018 |
Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Blood Glucose; Cytokines; Diabetes Mellitus, Ty | 2017 |
A new multifunctional hydroxytyrosol-fenofibrate with antidiabetic, antihyperlipidemic, antioxidant and antiinflammatory action.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Chemistry, Pharmaceutical; Diabetes Mellitus, Exper | 2017 |
Fenofibrate decreases the bone quality by down regulating Runx2 in high-fat-diet induced Type 2 diabetes mellitus mouse model.
Topics: Animals; Bone Density; Caspase 3; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Diabetes Mel | 2017 |
Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans | 2018 |
The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibr | 2018 |
Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy.
Topics: Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; | 2018 |
[CHANGES OF LIFETIME MORPHOLOGICAL PARAMETERS OF THE RETINA ON THE BACKGROUND OF CORRECTION OF LIPID METABOLISM IN PATIENTSWITH TYPE 2 DIABETES MELLITUS].
Topics: Aged; Biguanides; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; | 2017 |
Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature).
Topics: Amputation, Surgical; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate | 2018 |
[Management of hypertriglyceridaemia].
Topics: Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents | 2019 |
Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Hypolipidemic Agents; Lipids | 2018 |
Fenofibrate-induced rhabdomyolysis in a patient with stage 4 chronic renal failure due to diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Fenofibrate; Humans; Hypolipidemic Agent | 2012 |
An acute edematous pancreatitis case developed on the basis of hypertriglyceridemia.
Topics: Adult; Anticoagulants; Diabetes Mellitus, Type 2; Enzyme Activation; Female; Fenofibrate; Heparin; H | 2013 |
Altered expression profile of renal α(1D)-adrenergic receptor in diabetes and its modulation by PPAR agonists.
Topics: Animals; Cell Dedifferentiation; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Gen | 2014 |
Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Diabetes Mellitus, Type 2; Diet, Western; Fenofibrat | 2014 |
Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Excitat | 2015 |
Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina.
Topics: Animals; Apoptosis; Capillaries; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabeti | 2014 |
Network signatures link hepatic effects of anti-diabetic interventions with systemic disease parameters.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Progression; Fenofibrate; Hydrocarbons, Fluorinated; Liv | 2014 |
Systemic therapies for diabetic retinopathy: the accord eye study.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Human | 2014 |
Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Topics: Atherosclerosis; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fe | 2015 |
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysl | 2015 |
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana, Prevents Diabetes and Hyperlipidemia by Regulation of Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fenof | 2015 |
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
Topics: Aged; Apolipoprotein C-II; Aryldialkylphosphatase; Cardiovascular Diseases; Case-Control Studies; Di | 2016 |
Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibra | 2016 |
The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Topics: Adult; Age Factors; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Fema | 2016 |
PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.
Topics: Adult; Aged; Chemokine CCL5; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypertriglyceri | 2016 |
[Fibrates: their prescription must be restricted].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Fenofibrate; Fibric Acids; F | 2015 |
Thioredoxin interacting protein mediates lipid-induced impairment of glucose uptake in skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; | 2016 |
Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes-Associated Retinopathy.
Topics: ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Biomark | 2017 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fe | 2008 |
Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypolipidemic Agents; Metab | 2008 |
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietar | 2009 |
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydrotherapy; Hyperlipidemias; Hypolipidemic | 2008 |
Milky plasma, diabetes, and severe hyponatremia.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertension; Hyponat | 2009 |
Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Male; Metabolic Syndrome; Middle Aged | 2009 |
Fenofibrate and risk of minor amputations in diabetes.
Topics: Amputation, Surgical; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypol | 2009 |
Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; | 2009 |
Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.
Topics: Adiponectin; Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fibroblast | 2009 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Re | 2010 |
[HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
Topics: Apolipoprotein A-I; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; | 2010 |
ACCORD and Risk-Factor Control in Type 2 Diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combinati | 2010 |
Comparative analysis of fat and muscle proteins in fenofibrate-fed type II diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein.
Topics: Adaptor Proteins, Signal Transducing; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Diet; Elec | 2010 |
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Comb | 2010 |
Reduction in risk of progression of diabetic retinopathy.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug | 2010 |
[Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus].
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Evidence-Based Medicine; Fenofibrate; Hu | 2010 |
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Albuminuria; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerul | 2011 |
The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events.
Topics: Aged; Aged, 80 and over; Aging; Bilirubin; Clinical Laboratory Techniques; Creatine Kinase; Diabetes | 2011 |
[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; D | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2010 |
Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fen | 2010 |
[Lipid lowering, antiinflammatory, and vasoprotective effects of fenofibrate in patients with type 2 diabetes mellitus].
Topics: Adult; Aged; C-Reactive Protein; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Female | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidem | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fen | 2010 |
[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypolipidemic Agents | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: 2,3-Diphosphoglycerate; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofi | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypertens | 2010 |
Do fibrates truly preserve kidney function?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Humans; Kidney; Kidney Diseases | 2011 |
Use of fibrates in the United States and Canada.
Topics: Canada; Cardiovascular Diseases; Cohort Studies; Costs and Cost Analysis; Diabetes Mellitus, Type 2; | 2011 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipid | 2011 |
Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Topics: Animals; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2 | 2011 |
Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment.
Topics: Acute Disease; Adult; Biomarkers; Blood Glucose; Caloric Restriction; Diabetes Mellitus, Type 2; Fem | 2011 |
Fenofibrate: altered renal function.
Topics: Creatinine; Diabetes Mellitus, Type 2; Fenofibrate; Glomerular Filtration Rate; Humans; Hypolipidemi | 2011 |
Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy.
Topics: Aged; Aryldialkylphosphatase; Cells, Cultured; Cholesterol; Cholesterol, HDL; Cohort Studies; Diabet | 2011 |
Fibrate use in the United States and Canada.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Utilization; Dyslipid | 2011 |
Fibrate use in the United States and Canada.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Utilization; Dyslipidemias; Fenofibrate; Fi | 2011 |
Fibrates in the treatment of dyslipidemias--time for a reassessment.
Topics: Advisory Committees; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2011 |
PPAR ligands and cardiovascular disorders: friend or foe.
Topics: Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Glucose; Heart | 2012 |
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Femal | 2012 |
Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic | 2012 |
The work-up for mixed hyperlipidemia: a case study.
Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluor | 2012 |
Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Amputation, Surgical; Antioxidants; Bilirubin; Biomarkers; Cohort Studies; Diabetes Complicati | 2013 |
Diabetes, bilirubin and amputations: is there a link?
Topics: Amputation, Surgical; Bilirubin; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Fenofibr | 2013 |
Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.
Topics: Abdomen; Adipose Tissue; Animals; Body Weight; Carnitine O-Palmitoyltransferase; CD36 Antigens; Diab | 2002 |
Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
Topics: Adult; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol; Diabetes | 2002 |
[Coronary heart disease prevention in type 2 diabetic patients. What is the value of fibrates?].
Topics: Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofi | 2002 |
Fenofibrate monotherapy induced rhabdomyolysis.
Topics: Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Middl | 2003 |
Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Topics: Adipose Tissue; Animals; Basal Metabolism; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type | 2003 |
Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Catheterization; Cholesterol; Diabetes Mellitus, Ty | 2003 |
Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.
Topics: Animals; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Fenofibrate; Glycogen; Hypoglycemic Agent | 2004 |
Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations.
Topics: Adiponectin; Aged; Blood Glucose; Cytokines; Diabetes Mellitus, Lipoatrophic; Diabetes Mellitus, Typ | 2004 |
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
Topics: Apolipoprotein E2; Apolipoproteins E; Body Mass Index; Carrier Proteins; Cholesterol; Cholesterol Es | 2004 |
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cho | 2005 |
Simvastatin, fenofibrate, and rhabdomyolysis.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Hy | 2005 |
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
Topics: Aged; Apolipoprotein C-III; Apolipoproteins C; Body Mass Index; Diabetes Mellitus, Type 2; Female; F | 2005 |
A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas.
Topics: Diabetes Mellitus, Type 2; Erythrocyte Aggregation; Female; Fenofibrate; Humans; Hyperlipidemias; Hy | 2005 |
Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiop | 2005 |
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; | 2005 |
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Type | 2005 |
After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Feno | 2005 |
Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
Topics: Age Factors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofibrate; | 2006 |
[Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypoglycemic Agents; Hypoli | 2006 |
[Diabetes mellitus: types 1 & 2 increasingly similar].
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Mass Index; Child; Diabetes Complications; Diabetes Mel | 2006 |
[The FIELD study presented and published. Unconvincing results of fenofibrates in diabetic patients].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypolipidemic Agent | 2006 |
The FIELD study.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypolipidemic Agents; Morta | 2006 |
The FIELD study.
Topics: Diabetes Mellitus, Type 2; Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Risk Factors; Ve | 2006 |
[Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney].
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Kidney; Lipid Metabolism; M | 2006 |
The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Humans; Hypolipidemic Agent | 2006 |
PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Cells, Cultured; Collagen Type I; Diabetes Mellitu | 2006 |
Effects of long-term fenofibrate therapy on cardiovascular events in people with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypolipidemic Agents | 2006 |
Therapy and clinical trials.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fenofibrate; Humans; H | 2006 |
Elevation of CKP induced by ezetimibe in monotherapy: report on two cases.
Topics: Anticholesteremic Agents; Azetidines; Creatine Kinase; Creatinine; Diabetes Mellitus, Type 2; Ezetim | 2006 |
Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; H | 2006 |
[Change in ghrelin level with the amelioration of glucose and lipid metabolic disorder in OLETF rats].
Topics: Animals; Blotting, Northern; Diabetes Mellitus, Type 2; Fenofibrate; Gastric Mucosa; Ghrelin; Hypogl | 2006 |
Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.
Topics: Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Chemical and Drug Induced Liver Injury; Cholest | 2007 |
[Expediency of the use of fibrates for primary and secondary prevention of cardiovascular complications.].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Fibric Acids; Humans | 2006 |
Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Fenofibrate; Humans; Hypoglycemic Agent | 2007 |
Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Fenofibrate; Humans; Hypoglycemic Agent | 2007 |
Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
Topics: Aged; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Fem | 2008 |
The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; | 2007 |
Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Fen | 2007 |
The role of fenofibrate in clinical practice.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination | 2007 |
Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Glucose; Chole | 2008 |
PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats.
Topics: Actins; Animals; Blood Pressure; Blotting, Western; Collagen Type IV; Cyclin D1; Cytochrome P-450 CY | 2008 |
Fenofibrate and diabetic retinopathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Hypolipidemic Agents | 2008 |
Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy | 2007 |
[Relation between hypertriacylglycerolemia and the action of insulin in type 2 diabetes mellitus].
Topics: Adult; Aged; Clofibrate; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypertriglyceridemi | 1994 |
Detecting and correcting hyperlipidemia.
Topics: Algorithms; Decision Trees; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; | 1998 |
Status report of lipid-lowering trials in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease | 2000 |
Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Hum | 2001 |
[Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
Topics: Adult; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Disease Progression | 2001 |
Effect of lipanthyl in hyperlipoproteinaemic diabetic patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fe | 1989 |